-DOCSTART- -X- -X- -X- O

A	O
64	B-Age
year	I-Age
old	I-Age
female	O
known	O
for	O
HHT	B-Disease_disorder
is	O
referred	O
to	O
our	O
clinic	B-Nonbiological_location
for	O
recurrent	B-Detailed_description
epistaxis	B-Sign_symptom
for	O
nearly	B-Duration
50	I-Duration
years	I-Duration
.	O

She	O
has	O
had	O
recurrent	O
symptoms	O
since	O
the	O
age	O
of	O
16	O
when	O
her	O
condition	O
was	O
diagnosed	O
.	O

All	O
three	O
of	O
her	O
siblings	O
also	O
were	O
diagnosed	O
with	O
HHT	O
and	O
her	O
mother	O
passed	O
away	O
from	O
an	O
intracranial	O
hemorrhage	O
.	O

Eight	O
years	O
prior	O
to	O
presentation	O
she	O
had	O
undergone	O
a	O
left	B-Detailed_description
-	I-Detailed_description
sided	I-Detailed_description
septodermoplasty	B-Therapeutic_procedure
via	O
a	O
lateral	B-Detailed_description
rhinotomy	B-Therapeutic_procedure
approach	O
.	O

This	O
operation	O
had	O
significantly	O
reduced	O
the	O
frequency	O
of	O
her	O
symptoms	B-Sign_symptom
and	O
for	B-Duration
several	I-Duration
years	I-Duration
her	O
epistaxis	B-Sign_symptom
was	O
under	B-Lab_value
control	I-Lab_value
with	O
the	O
use	O
of	O
low	B-Dosage
dose	I-Dosage
thalidomide	B-Medication
.	O

However	O
,	O
she	O
was	O
referred	O
to	O
our	O
clinic	B-Nonbiological_location
due	O
to	O
increased	B-Detailed_description
epistaxis	B-Sign_symptom
severity	B-Severity
and	O
frequency	B-Frequency
over	B-Duration
the	I-Duration
prior	I-Duration
12	I-Duration
months	I-Duration
necessitating	O
more	O
frequent	O
transfusions	B-Therapeutic_procedure
.	O

At	O
the	O
time	O
of	O
consultation	O
the	O
patient	O
was	O
concerned	O
about	O
daily	B-Frequency
severe	B-Severity
left	B-Biological_structure
sided	I-Biological_structure
epistaxis	B-Sign_symptom
despite	O
several	B-Duration
months	I-Duration
use	O
of	O
topical	O
bevacizumab	B-Medication
and	O
oral	O
tranexamic	B-Medication
acid	I-Medication
.	O

She	O
required	O
intravenous	O
iron	B-Medication
and	O
blood	B-Therapeutic_procedure
transfusions	I-Therapeutic_procedure
every	B-Frequency
two	I-Frequency
months	I-Frequency
.	O

Her	O
baseline	O
hemoglobin	B-Diagnostic_procedure
at	O
the	O
time	O
of	O
our	O
consultation	O
was	O
75	B-Lab_value
g	I-Lab_value
/	I-Lab_value
L	I-Lab_value
(	O
normal	O
=	O
120	O
-	O
160	O
g	O
/	O
L	O
)	O
.	O

Her	O
HHT	B-Diagnostic_procedure
epistaxis	I-Diagnostic_procedure
severity	I-Diagnostic_procedure
score	I-Diagnostic_procedure
[	O
17	O
]	O
was	O
severe	B-Lab_value
(	O
normalized	B-Lab_value
score	I-Lab_value
9	I-Lab_value
.	I-Lab_value
49	I-Lab_value
)	O
.	O

On	O
examination	B-Diagnostic_procedure
,	O
she	O
had	O
multiple	B-Detailed_description
telangiectasia	B-Sign_symptom
on	O
her	O
fingers	B-Biological_structure
,	O
face	B-Biological_structure
,	O
lips	B-Biological_structure
and	O
palate	B-Biological_structure
.	O

Her	O
endoscopic	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
revealed	O
bilateral	B-Detailed_description
telangiectasia	B-Sign_symptom
along	O
the	O
nasal	B-Biological_structure
septum	I-Biological_structure
.	O

There	O
was	O
extensive	B-Severity
crusting	B-Sign_symptom
along	O
the	O
entire	O
left	B-Biological_structure
nasal	I-Biological_structure
cavity	I-Biological_structure
with	O
which	O
any	O
manipulation	B-Diagnostic_procedure
resulted	O
in	O
immediate	B-Detailed_description
profuse	B-Severity
epistaxis	B-Sign_symptom
.	O

Given	O
the	O
severity	O
of	O
the	O
patient	O
`	O
s	O
epistaxis	O
despite	O
medical	O
therapy	O
,	O
she	O
was	O
offered	O
endoscopic	B-Detailed_description
left	B-Detailed_description
-	I-Detailed_description
sided	I-Detailed_description
septodermoplasty	B-Therapeutic_procedure
.	O

The	O
surgical	O
goals	O
were	O
to	O
improve	O
her	O
quality	O
of	O
life	O
by	O
reducing	O
the	O
number	O
and	O
severity	O
of	O
epistaxis	O
episodes	O
while	O
diminishing	O
the	O
need	O
for	O
blood	O
transfusions	O
.	O

The	O
patient	O
was	O
content	O
with	O
the	O
treatment	O
plan	O
and	O
agreed	O
to	O
undergo	O
surgical	O
intervention	O
.	O

The	O
endoscopic	B-Therapeutic_procedure
procedure	I-Therapeutic_procedure
was	O
performed	O
under	O
general	B-Medication
anesthesia	I-Medication
with	O
endotracheal	B-Detailed_description
intubation	B-Therapeutic_procedure
.	O

The	O
nasal	B-Biological_structure
cavity	I-Biological_structure
was	O
prepared	B-Therapeutic_procedure
by	O
inserting	B-Detailed_description
pledgets	I-Detailed_description
soaked	O
in	O
topical	O
adrenaline	B-Medication
(	O
1:1000	B-Dosage
)	O
placed	O
in	O
both	B-Biological_structure
nostrils	I-Biological_structure
for	O
decongestion	O
.	O

Using	B-Detailed_description
a	I-Detailed_description
zero	I-Detailed_description
degree	I-Detailed_description
endoscope	I-Detailed_description
the	O
residual	B-Biological_structure
STSG	I-Biological_structure
and	I-Biological_structure
mucosa	I-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
left	I-Biological_structure
septum	I-Biological_structure
was	O
dissected	B-Therapeutic_procedure
in	B-Detailed_description
a	I-Detailed_description
supraperichondrial	I-Detailed_description
plane	I-Detailed_description
that	O
resulted	O
in	O
the	O
expected	O
significant	B-Severity
diffuse	B-Detailed_description
hemorrhage	B-Sign_symptom
.	O

Immediate	B-Detailed_description
hemostasis	B-Therapeutic_procedure
was	O
attained	O
using	O
a	O
topical	B-Detailed_description
gelatin	I-Detailed_description
-	I-Detailed_description
thrombin	I-Detailed_description
matrix	I-Detailed_description
,	O
Floseal	B-Detailed_description
(	O
FloSeal	O
Hemostatic	O
Matrix	O
;	O
Baxter	O
Healthcare	O
Corporation	O
,	O
Deerfield	O
,	O
IL	O
,	O
USA	O
)	O
(	O
Fig	O
.	O
1	O
)	O
.	O

The	O
mucosal	B-Sign_symptom
defect	I-Sign_symptom
(	O
Fig	O
.	O
2	O
)	O
measured	O
approximately	O
3	B-Distance
cm	I-Distance
in	O
anterior	B-Detailed_description
-	I-Detailed_description
posterior	I-Detailed_description
dimension	I-Detailed_description
.	O

A	O
4	B-Area
x	I-Area
2	I-Area
cm	I-Area
split	I-Area
thickness	I-Area
skin	B-Therapeutic_procedure
graft	I-Therapeutic_procedure
was	I-Therapeutic_procedure
harvested	I-Therapeutic_procedure
from	O
the	O
right	B-Biological_structure
thigh	I-Biological_structure
,	O
pie	B-Detailed_description
-	I-Detailed_description
crusted	I-Detailed_description
with	I-Detailed_description
a	I-Detailed_description
15	I-Detailed_description
blade	I-Detailed_description
and	O
then	O
placed	B-Detailed_description
endoscopically	I-Detailed_description
along	B-Biological_structure
the	I-Biological_structure
length	I-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
septal	I-Biological_structure
defect	I-Biological_structure
.	O

As	O
seen	O
in	O
Fig	O
.	O
3	O
,	O
the	O
graft	O
was	O
placed	O
with	O
an	O
overlap	B-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
mucosa	I-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
nasal	I-Biological_structure
floor	I-Biological_structure
and	I-Biological_structure
the	I-Biological_structure
residual	I-Biological_structure
superior	I-Biological_structure
septal	I-Biological_structure
mucosa	I-Biological_structure
.	O

Finally	O
,	O
2	B-Volume
mL	I-Volume
of	O
fibrin	B-Detailed_description
sealant	I-Detailed_description
(	O
TISSEEL	O
fibrin	O
sealant	O
,	O
Baxter	O
Healthcare	O
Corporation	O
,	O
Deerfield	O
,	O
IL	O
,	O
USA	O
)	O
was	O
then	O
applied	B-Detailed_description
first	I-Detailed_description
to	I-Detailed_description
the	I-Detailed_description
edges	I-Detailed_description
then	I-Detailed_description
central	I-Detailed_description
portion	I-Detailed_description
of	I-Detailed_description
the	I-Detailed_description
STSG	I-Detailed_description
(	O
Fig	O
.	O
4	O
)	O
.	O

Packing	B-Therapeutic_procedure
was	O
not	O
used	O
post	O
-	O
operatively	O
and	O
the	O
patient	O
was	O
discharged	O
home	B-Nonbiological_location
on	O
the	O
same	O
day	O
of	O
surgery	O
.	O

Clinical	O
follow	O
-	O
up	O
two	O
weeks	O
after	O
surgery	O
(	O
Fig	O
.	O
5	O
)	O
showed	O
that	O
the	O
entire	O
graft	B-Sign_symptom
had	I-Sign_symptom
taken	I-Sign_symptom
and	O
the	O
left	B-Detailed_description
-	I-Detailed_description
sided	I-Detailed_description
epistaxis	B-Sign_symptom
had	O
dramatically	O
diminished	O
.	O

The	O
patient	O
was	O
very	O
content	O
with	O
the	O
results	O
of	O
the	O
procedure	O
.	O

At	O
6	O
months	O
follow	O
-	O
up	O
,	O
her	O
baseline	O
hemoglobin	B-Diagnostic_procedure
had	O
improved	O
to	O
102	B-Lab_value
g	I-Lab_value
/	I-Lab_value
L	I-Lab_value
and	O
she	O
was	O
requiring	O
transfusions	B-Therapeutic_procedure
every	B-Frequency
4	I-Frequency
months	I-Frequency
with	O
her	O
hematologist	O
`	O
s	O
intent	O
to	O
stop	O
the	O
transfusions	O
if	O
her	O
hemoglobin	O
remained	O
greater	O
than	O
100	O
g	O
/	O
L	O
.	O

Her	O
epistaxis	B-Diagnostic_procedure
severity	I-Diagnostic_procedure
score	I-Diagnostic_procedure
at	O
6	O
month	O
follow	O
up	O
was	O
mild	B-Lab_value
(	O
normalized	B-Lab_value
score	I-Lab_value
3	I-Lab_value
.	I-Lab_value
05	I-Lab_value
)	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
45	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
lady	O
sought	O
dermatology	O
consultation	O
for	O
severely	B-Texture
tender	I-Texture
erythematous	B-Detailed_description
vesicles	B-Sign_symptom
and	O
bullae	B-Sign_symptom
over	O
back	B-Biological_structure
,	O
chest	B-Biological_structure
and	O
arms	B-Biological_structure
.	O

These	O
were	O
sudden	B-Detailed_description
in	I-Detailed_description
onset	I-Detailed_description
associated	O
with	O
fever	B-Sign_symptom
,	O
nausea	B-Sign_symptom
and	O
malaise	B-Sign_symptom
.	O

Along	O
with	O
this	O
she	O
also	O
complained	O
of	O
pain	B-Sign_symptom
in	O
upper	B-Biological_structure
abdomen	I-Biological_structure
.	O

There	O
was	O
no	O
history	O
of	O
receiving	O
any	O
drugs	B-Medication
prior	B-Time
to	I-Time
the	I-Time
onset	I-Time
of	I-Time
lesions	I-Time
.	O

She	O
did	O
not	O
report	O
any	O
significant	B-Detailed_description
weight	B-Sign_symptom
loss	I-Sign_symptom
or	O
loss	B-Sign_symptom
of	I-Sign_symptom
appetite	I-Sign_symptom
.	O

On	O
physical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
,	O
her	O
temperature	B-Diagnostic_procedure
was	O
38	B-Lab_value
°C	I-Lab_value
,	O
pulse	B-Diagnostic_procedure
rate	I-Diagnostic_procedure
was	O
100	B-Lab_value
/	I-Lab_value
min	I-Lab_value
and	O
blood	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
was	O
126	B-Lab_value
/	I-Lab_value
72	I-Lab_value
mm	I-Lab_value
Hg	I-Lab_value
.	O

There	O
were	O
multiple	B-Lab_value
coalescing	B-Detailed_description
vesicles	O
and	O
bullae	O
over	O
upper	B-Biological_structure
back	I-Biological_structure
,	O
chest	B-Biological_structure
and	O
arms	B-Biological_structure
distributed	B-Detailed_description
symmetrically	I-Detailed_description
showing	O
areas	O
of	O
pustulation	B-Sign_symptom
and	O
necrosis	B-Sign_symptom
.	O

Surrounding	B-Other_entity
them	O
were	O
multiple	B-Lab_value
pseudovesicular	B-Detailed_description
satellite	B-Detailed_description
papule	B-Sign_symptom
(	O
figure	O
1A	O
,	O
B	O
)	O
.	O

On	O
per	O
abdominal	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
mild	B-Severity
tenderness	B-Sign_symptom
was	O
present	O
in	O
the	O
right	B-Biological_structure
hypochondrium	I-Biological_structure
.	O

Patient	O
`	O
s	O
initial	O
laboratory	B-Diagnostic_procedure
investigations	I-Diagnostic_procedure
showed	O
a	O
total	B-Diagnostic_procedure
leucocyte	I-Diagnostic_procedure
count	I-Diagnostic_procedure
of	O
12	B-Lab_value
000	I-Lab_value
cells	I-Lab_value
/	I-Lab_value
mm3	I-Lab_value
with	O
75	B-Lab_value
%	I-Lab_value
neutrophils	I-Lab_value
.	O

The	O
haemoglobin	B-Diagnostic_procedure
level	O
was	O
14	B-Lab_value
.	I-Lab_value
3	I-Lab_value
gm	I-Lab_value
%	I-Lab_value
and	O
erythrocyte	B-Diagnostic_procedure
sedimentation	I-Diagnostic_procedure
rate	I-Diagnostic_procedure
was	O
30	B-Lab_value
mm	I-Lab_value
/	I-Lab_value
h	I-Lab_value
.	O

Liver	B-Diagnostic_procedure
function	I-Diagnostic_procedure
test	I-Diagnostic_procedure
,	O
kidney	B-Diagnostic_procedure
function	I-Diagnostic_procedure
test	I-Diagnostic_procedure
and	O
C	B-Diagnostic_procedure
reactive	I-Diagnostic_procedure
protein	I-Diagnostic_procedure
levels	O
were	O
within	O
normal	B-Lab_value
limits	O
.	O

Gram	B-Diagnostic_procedure
stain	I-Diagnostic_procedure
from	O
purulent	B-Diagnostic_procedure
exudates	I-Diagnostic_procedure
showed	O
only	O
neutrophils	B-Biological_structure
without	O
any	O
organisms	B-Sign_symptom
and	O
culture	B-Diagnostic_procedure
did	O
not	O
show	O
any	O
growth	B-Sign_symptom
after	O
72	B-Duration
h	I-Duration
of	I-Duration
incubation	I-Duration
.	O

A	O
lesional	B-Detailed_description
skin	B-Biological_structure
biopsy	B-Diagnostic_procedure
taken	O
from	O
the	O
satellite	B-Detailed_description
papule	O
showed	O
neutrophilic	B-Sign_symptom
infiltration	I-Sign_symptom
in	O
dermis	B-Biological_structure
with	O
papillary	B-Sign_symptom
dermal	I-Sign_symptom
oedema	I-Sign_symptom
and	O
spongiosis	B-Sign_symptom
(	O
figure	O
2A	O
,	O
B	O
)	O
.	O

Abdominal	B-Biological_structure
ultrasonography	B-Diagnostic_procedure
revealed	O
intraluminal	B-Detailed_description
gall	B-Biological_structure
bladder	I-Biological_structure
mass	B-Sign_symptom
suggestive	O
of	O
malignancy	B-Sign_symptom
.	O

On	O
the	O
basis	O
of	O
these	O
findings	O
a	O
final	O
diagnosis	O
of	O
SS	B-Disease_disorder
associated	O
with	O
gall	O
bladder	O
malignancy	O
was	O
made	O
.	O

She	O
was	O
started	O
on	O
oral	O
prednisolone	B-Medication
in	O
dose	O
of	O
40	B-Dosage
mg	I-Dosage
daily	B-Frequency
along	O
with	O
symptomatic	B-Detailed_description
treatment	B-Medication
.	O

Her	O
cutaneous	B-Detailed_description
lesions	B-Sign_symptom
responded	O
dramatically	O
and	O
subsided	B-Detailed_description
completely	I-Detailed_description
after	O
1	B-Duration
week	I-Duration
of	O
treatment	B-Medication
(	O
figure	O
3A	O
,	O
B	O
)	O
.	O

Dose	O
of	O
prednisolone	O
was	O
tapered	O
and	O
an	O
open	B-Detailed_description
cholecystectomy	B-Therapeutic_procedure
was	O
performed	O
.	O

Histopathology	B-Diagnostic_procedure
of	O
excised	B-Biological_structure
tissue	I-Biological_structure
confirmed	O
it	O
to	O
be	O
well	B-Detailed_description
-	I-Detailed_description
differentiated	I-Detailed_description
gall	B-Biological_structure
bladder	I-Biological_structure
adenocarcinoma	B-Disease_disorder
forming	O
glands	B-Sign_symptom
and	I-Sign_symptom
papillae	B-Biological_structure
infiltrating	B-Sign_symptom
the	I-Sign_symptom
muscularis	B-Biological_structure
propria	I-Biological_structure
superficially	B-Detailed_description
.	O

Cystic	B-Biological_structure
duct	I-Biological_structure
cut	I-Biological_structure
margins	I-Biological_structure
were	O
free	O
of	O
tumour	B-Sign_symptom
(	O
figure	O
2C	O
,	O
D	O
)	O
.	O

Patient	O
`	O
s	O
postoperative	B-Duration
period	I-Duration
was	O
uneventful	B-Sign_symptom
and	O
she	O
was	O
discharged	O
on	O
tapering	B-Dosage
doses	I-Dosage
of	O
prednisolone	O
with	O
advice	O
to	O
follow	O
-	O
up	O
periodically	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
44	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
man	O
had	O
been	O
diagnosed	O
with	O
LCNEC	B-Disease_disorder
of	O
the	O
thymus	B-Biological_structure
with	O
bone	B-Biological_structure
metastasis	B-Sign_symptom
at	O
a	O
different	B-Nonbiological_location
hospital	I-Nonbiological_location
3	O
years	O
previously	O
.	O

The	O
serum	O
levels	O
of	O
ACTH	B-Diagnostic_procedure
and	O
cortisol	B-Diagnostic_procedure
were	O
elevated	B-Lab_value
,	O
but	O
brain	B-Biological_structure
magnetic	B-Diagnostic_procedure
resonance	I-Diagnostic_procedure
imaging	I-Diagnostic_procedure
revealed	O
that	O
his	O
pituitary	B-Detailed_description
gland	I-Detailed_description
was	O
normal	B-Lab_value
.	O

However	O
,	O
immunohistochemical	B-Diagnostic_procedure
staining	I-Diagnostic_procedure
of	O
the	O
thymic	B-Biological_structure
tumor	I-Biological_structure
tissue	I-Biological_structure
revealed	O
partial	B-Lab_value
anti	B-Diagnostic_procedure
-	I-Diagnostic_procedure
ACTH	I-Diagnostic_procedure
antibody	I-Diagnostic_procedure
positivity	B-Lab_value
.	O

The	O
tumor	O
was	O
therefore	O
determined	O
to	O
be	O
ectopically	B-Detailed_description
producing	I-Detailed_description
ACTH	I-Detailed_description
.	O

The	O
patient	O
underwent	O
chemotherapy	B-Medication
with	O
cisplatin	B-Medication
and	O
irinotecan	B-Medication
,	O
but	O
the	O
continuation	O
of	O
chemotherapy	O
was	O
problematic	B-Detailed_description
due	I-Detailed_description
to	I-Detailed_description
a	I-Detailed_description
lack	I-Detailed_description
of	I-Detailed_description
tolerance	I-Detailed_description
.	O

Treatment	O
for	O
hypertension	B-Sign_symptom
and	O
diabetes	B-Disease_disorder
caused	O
by	O
the	O
ectopic	B-Disease_disorder
ACTH	I-Disease_disorder
syndrome	I-Disease_disorder
was	O
initiated	O
,	O
as	O
was	O
treatment	O
with	O
zoledronic	B-Medication
acid	I-Medication
for	O
bone	B-Biological_structure
metastasis	B-Sign_symptom
.	O

The	O
patient	O
was	O
referred	O
to	O
the	O
Endocrine	B-Nonbiological_location
Center	I-Nonbiological_location
at	I-Nonbiological_location
our	I-Nonbiological_location
hospital	I-Nonbiological_location
after	O
3	O
months	O
due	O
to	O
a	O
sensation	B-Sign_symptom
of	I-Sign_symptom
weakness	I-Sign_symptom
and	O
the	O
worsening	O
of	O
his	O
hyperglycemia	B-Sign_symptom
.	O

A	O
physical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
revealed	O
hypertension	B-Sign_symptom
,	O
a	O
subcutaneous	B-Detailed_description
mass	B-Sign_symptom
that	O
was	O
palpable	B-Detailed_description
in	O
the	O
anterior	B-Biological_structure
chest	I-Biological_structure
,	O
and	O
redness	B-Sign_symptom
and	O
swelling	B-Sign_symptom
of	O
the	O
left	B-Biological_structure
lower	I-Biological_structure
leg	I-Biological_structure
without	O
fever	B-Sign_symptom
,	O
respiratory	B-Sign_symptom
symptoms	I-Sign_symptom
,	O
hypoxemia	B-Sign_symptom
,	O
or	O
abnormal	B-Sign_symptom
chest	I-Sign_symptom
sounds	I-Sign_symptom
.	O

The	O
oxygen	B-Diagnostic_procedure
saturation	I-Diagnostic_procedure
by	O
pulse	B-Detailed_description
oximeter	I-Detailed_description
in	O
room	B-Detailed_description
air	I-Detailed_description
and	O
was	O
97	B-Lab_value
%	I-Lab_value
and	O
his	O
respiratory	B-Diagnostic_procedure
rate	I-Diagnostic_procedure
was	O
13	B-Lab_value
breaths	I-Lab_value
per	I-Lab_value
minute	I-Lab_value
.	O

Among	O
the	O
laboratory	B-Diagnostic_procedure
findings	I-Diagnostic_procedure
,	O
the	O
white	B-Diagnostic_procedure
blood	I-Diagnostic_procedure
cell	I-Diagnostic_procedure
and	O
neutrophil	B-Diagnostic_procedure
counts	O
,	O
and	O
blood	B-Diagnostic_procedure
sugar	I-Diagnostic_procedure
,	O
triglyceride	B-Diagnostic_procedure
,	O
and	O
low	B-Diagnostic_procedure
-	I-Diagnostic_procedure
density	I-Diagnostic_procedure
lipoprotein	I-Diagnostic_procedure
cholesterol	I-Diagnostic_procedure
levels	O
were	O
found	O
to	O
be	O
elevated	B-Lab_value
,	O
and	O
the	O
patient	O
`	O
s	O
potassium	B-Diagnostic_procedure
level	O
was	O
decreased	B-Lab_value
to	O
2	B-Lab_value
.	I-Lab_value
8	I-Lab_value
mEq	I-Lab_value
/	I-Lab_value
L	I-Lab_value
.	O

The	O
patient	O
`	O
s	O
lactate	B-Diagnostic_procedure
dehydrogenase	I-Diagnostic_procedure
(	O
468	B-Lab_value
IU	I-Lab_value
/	I-Lab_value
L	I-Lab_value
)	O
,	O
beta	B-Diagnostic_procedure
-	I-Diagnostic_procedure
D	I-Diagnostic_procedure
glucan	I-Diagnostic_procedure
(	O
370	B-Lab_value
.	I-Lab_value
8	I-Lab_value
pg	I-Lab_value
/	I-Lab_value
mL	I-Lab_value
)	O
,	O
ACTH	B-Diagnostic_procedure
(	O
354	B-Lab_value
.	I-Lab_value
1	I-Lab_value
pg	I-Lab_value
/	I-Lab_value
mL	I-Lab_value
)	O
,	O
and	O
cortisol	B-Diagnostic_procedure
(	O
49	B-Lab_value
.	I-Lab_value
1	I-Lab_value
μg	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
)	O
levels	O
were	O
also	O
elevated	B-Lab_value
.	O

The	O
patient	O
`	O
s	O
serum	B-Diagnostic_procedure
was	O
negative	B-Lab_value
for	O
aspergillus	B-Diagnostic_procedure
,	O
candida	B-Diagnostic_procedure
,	O
and	O
cryptococcus	B-Diagnostic_procedure
antigens	I-Diagnostic_procedure
;	O
a	O
cytomegalovirus	B-Diagnostic_procedure
pp65	I-Diagnostic_procedure
antigenemia	I-Diagnostic_procedure
test	I-Diagnostic_procedure
also	O
yielded	O
a	O
negative	B-Lab_value
result	O
.	O

These	O
data	O
suggested	O
that	O
the	O
increased	O
production	O
of	O
ACTH	O
by	O
the	O
tumor	O
,	O
along	O
with	O
the	O
progression	O
of	O
the	O
disease	O
,	O
had	O
promoted	O
the	O
elevation	O
of	O
the	O
patient	O
`	O
s	O
serum	O
levels	O
of	O
ACTH	O
and	O
cortisol	O
.	O

Computed	B-Diagnostic_procedure
tomography	I-Diagnostic_procedure
(	O
CT	B-Diagnostic_procedure
)	O
revealed	O
the	O
progression	B-Sign_symptom
of	I-Sign_symptom
the	I-Sign_symptom
disease	I-Sign_symptom
in	O
the	O
both	O
thymic	B-Biological_structure
and	O
metastatic	B-Detailed_description
bone	B-Biological_structure
lesions	B-Sign_symptom
,	O
along	O
with	O
the	O
multiple	B-Detailed_description
ground	B-Texture
-	I-Texture
glass	I-Texture
opacities	B-Sign_symptom
in	O
both	B-Biological_structure
lungs	I-Biological_structure
(	O
Fig	O
.	O
1	O
,	O
2	O
)	O
.	O

The	O
patient	O
underwent	O
bronchoalveolar	B-Diagnostic_procedure
lavage	I-Diagnostic_procedure
(	O
BAL	B-Diagnostic_procedure
)	O
in	O
the	O
right	B-Biological_structure
B5	I-Biological_structure
segment	I-Biological_structure
with	O
150	B-Detailed_description
mL	I-Detailed_description
saline	I-Detailed_description
,	O
and	O
62	B-Lab_value
.	I-Lab_value
7	I-Lab_value
%	I-Lab_value
of	I-Lab_value
the	I-Lab_value
BAL	I-Lab_value
fluid	I-Lab_value
was	I-Lab_value
recovered	I-Lab_value
.	O

The	O
cell	B-Diagnostic_procedure
count	I-Diagnostic_procedure
in	O
the	O
BAL	B-Detailed_description
fluid	I-Detailed_description
was	O
0	B-Lab_value
.	I-Lab_value
61	I-Lab_value
×	I-Lab_value
105	I-Lab_value
per	I-Lab_value
mL	I-Lab_value
,	O
and	O
the	O
cell	B-Diagnostic_procedure
differentiation	I-Diagnostic_procedure
in	O
the	O
BAL	B-Detailed_description
fluid	I-Detailed_description
was	O
17	B-Lab_value
.	I-Lab_value
0	I-Lab_value
%	I-Lab_value
macrophages	I-Lab_value
,	O
81	B-Lab_value
.	I-Lab_value
0	I-Lab_value
%	I-Lab_value
lymphocytes	I-Lab_value
,	O
and	O
2	B-Lab_value
.	I-Lab_value
0	I-Lab_value
%	I-Lab_value
neutrophils	I-Lab_value
,	O
with	O
a	O
CD	B-Lab_value
4	I-Lab_value
/	I-Lab_value
8	I-Lab_value
ratio	I-Lab_value
of	I-Lab_value
0	I-Lab_value
.	I-Lab_value
57	I-Lab_value
.	O

Gram	B-Diagnostic_procedure
,	O
Ziehl	B-Diagnostic_procedure
-	I-Diagnostic_procedure
Neelsen	I-Diagnostic_procedure
,	O
and	O
Grocott	B-Diagnostic_procedure
staining	I-Diagnostic_procedure
were	O
all	O
negative	B-Lab_value
.	O

A	O
polymerase	B-Diagnostic_procedure
chain	I-Diagnostic_procedure
reaction	I-Diagnostic_procedure
revealed	O
that	O
the	O
patient	O
`	O
s	O
BAL	B-Detailed_description
fluid	I-Detailed_description
was	O
positive	B-Lab_value
for	O
Pneumocystis	B-Diagnostic_procedure
jirovecii	I-Diagnostic_procedure
.	O

PCP	B-Disease_disorder
was	O
diagnosed	O
based	O
on	O
the	O
above	O
results	O
.	O

The	O
patient	O
was	O
treated	O
with	O
sulfamethoxazole	B-Medication
/	I-Medication
trimethoprim	I-Medication
(	O
12	B-Dosage
g	I-Dosage
/	I-Dosage
day	I-Dosage
)	O
for	O
3	B-Duration
weeks	I-Duration
.	O

Anti	B-Therapeutic_procedure
-	I-Therapeutic_procedure
cortisol	I-Therapeutic_procedure
therapy	I-Therapeutic_procedure
with	O
metyrapone	B-Medication
was	O
also	O
initiated	O
at	O
the	O
same	O
time	O
with	O
a	O
small	B-Dosage
dose	I-Dosage
to	O
slowly	O
correct	O
the	O
hypercortisolemia	B-Disease_disorder
.	O

Intensive	O
insulin	B-Medication
therapy	O
,	O
potassium	B-Medication
supplementation	O
were	O
initiated	O
,	O
while	O
cefazolin	B-Medication
was	O
administered	O
to	O
treat	O
cellulitis	B-Disease_disorder
of	O
the	O
left	B-Biological_structure
lower	I-Biological_structure
leg	I-Biological_structure
.	O

The	O
patient	O
`	O
s	O
PCP	B-Disease_disorder
fully	O
improved	O
without	O
the	O
exacerbation	B-Sign_symptom
of	O
his	O
respiratory	B-Diagnostic_procedure
status	I-Diagnostic_procedure
.	O

Thereafter	O
,	O
we	O
continued	O
to	O
administer	O
sulfamethoxazole	B-Medication
/	I-Medication
trimethoprim	I-Medication
at	O
a	O
prophylactic	B-Dosage
dose	I-Dosage
.	O

The	O
metyrapone	B-Medication
dosage	O
was	O
gradually	O
increased	O
from	O
250	B-Dosage
mg	I-Dosage
/	I-Dosage
day	I-Dosage
,	O
and	O
the	O
blood	B-Diagnostic_procedure
cortisol	I-Diagnostic_procedure
value	O
was	O
observed	O
to	O
decline	B-Lab_value
slowly	I-Lab_value
(	O
Fig	O
.	O
3	O
)	O
.	O

In	O
order	O
to	O
prevent	O
hypocortisolemia	O
,	O
the	O
patient	O
was	O
temporarily	B-Detailed_description
treated	O
with	O
hydrocortisone	B-Medication
.	O

After	O
an	O
improvement	O
of	O
his	O
left	B-Biological_structure
lower	I-Biological_structure
leg	I-Biological_structure
cellulitis	B-Disease_disorder
,	O
PCP	B-Disease_disorder
,	O
and	O
hyperglycemia	B-Disease_disorder
,	O
the	O
patient	O
underwent	O
laminectomy	B-Therapeutic_procedure
and	O
radiation	B-Therapeutic_procedure
therapy	I-Therapeutic_procedure
for	O
spinal	B-Disease_disorder
cord	I-Disease_disorder
compression	I-Disease_disorder
,	O
which	O
had	O
been	O
caused	O
by	O
a	O
metastatic	B-Detailed_description
spinal	B-Biological_structure
tumor	B-Sign_symptom
.	O

Octreotide	B-Medication
therapy	O
was	O
initiated	O
,	O
and	O
he	O
was	O
discharged	O
on	O
the	O
68th	O
day	O
of	O
hospitalization	O
.	O

-DOCSTART- -X- -X- -X- O

Our	O
patient	O
was	O
a	O
7	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
Italian	O
boy	O
born	O
after	O
an	O
uneventful	O
gestation	O
of	O
normal	O
duration	O
.	O

At	O
the	O
age	O
of	O
16	O
months	O
,	O
he	O
presented	O
with	O
a	O
clinically	B-Detailed_description
evident	I-Detailed_description
enlarged	B-Sign_symptom
abdomen	B-Biological_structure
and	O
was	O
referred	O
for	O
oncological	B-Nonbiological_location
examination	I-Nonbiological_location
.	O

Initial	O
tests	O
revealed	O
anemia	B-Sign_symptom
,	O
thrombocytopenia	B-Sign_symptom
,	O
and	O
splenomegaly	B-Sign_symptom
.	O

A	O
bone	B-Biological_structure
marrow	I-Biological_structure
biopsy	B-Diagnostic_procedure
revealed	O
the	O
presence	O
of	O
foam	B-Sign_symptom
cells	I-Sign_symptom
,	O
which	O
led	O
to	O
suspicion	O
of	O
lysosomal	B-Disease_disorder
storage	I-Disease_disorder
disease	I-Disease_disorder
.	O

Biochemical	B-Diagnostic_procedure
testing	I-Diagnostic_procedure
revealed	O
elevated	B-Lab_value
level	O
of	O
acid	B-Diagnostic_procedure
phosphatase	I-Diagnostic_procedure
(	O
47	B-Lab_value
.	I-Lab_value
8	I-Lab_value
IU	I-Lab_value
/	I-Lab_value
L	I-Lab_value
[	O
normal	O
range	O
5	O
-	O
7	O
IU	O
/	O
L	O
]	O
)	O
and	O
chitotriosidase	B-Diagnostic_procedure
activity	I-Diagnostic_procedure
(	O
508	B-Lab_value
nmol	I-Lab_value
/	I-Lab_value
mg	I-Lab_value
protein	I-Lab_value
[	O
normal	O
range	O
5	O
.	O
9	O
-	O
41	O
.	O
0	O
nmol	O
/	O
mg	O
protein	O
]	O
)	O
,	O
as	O
well	O
as	O
reduced	B-Lab_value
beta	B-Diagnostic_procedure
-	I-Diagnostic_procedure
glucosidase	I-Diagnostic_procedure
activity	I-Diagnostic_procedure
(	O
2	B-Lab_value
nmol	I-Lab_value
/	I-Lab_value
mg	I-Lab_value
/	I-Lab_value
protein	I-Lab_value
[	O
normal	O
range	O
4	O
.	O
5	O
-	O
18	O
.	O
0	O
nmol	O
/	O
mg	O
/	O
protein	O
]	O
)	O
.	O

Molecular	B-Diagnostic_procedure
analysis	I-Diagnostic_procedure
showed	O
homozygous	B-Detailed_description
L444P	B-Detailed_description
mutations	B-Sign_symptom
in	I-Sign_symptom
the	I-Sign_symptom
GBA	I-Sign_symptom
gene	I-Sign_symptom
(	O
OMIM	O
reference	O
606463	O
)	O
,	O
confirming	O
the	O
diagnosis	O
of	O
chronic	O
NGD	B-Disease_disorder
.	O

The	O
patient	O
began	O
ERT	B-Therapeutic_procedure
at	O
a	O
dosage	O
of	O
60	B-Dosage
U	I-Dosage
/	I-Dosage
kg	I-Dosage
every	I-Dosage
2	I-Dosage
weeks	I-Dosage
at	O
the	O
age	O
of	O
18	O
months	O
.	O

Thereafter	O
,	O
when	O
the	O
patient	O
reached	O
the	O
age	O
of	O
30	O
months	O
,	O
we	O
decided	O
to	O
combine	O
ERT	B-Therapeutic_procedure
with	O
SRT	B-Therapeutic_procedure
with	O
miglustat	B-Medication
.	O

This	O
clinical	O
decision	O
was	O
approved	O
by	O
our	O
institution	O
`	O
s	O
ethics	O
committee	O
,	O
and	O
informed	O
consent	O
was	O
obtained	O
from	O
the	O
patient	O
`	O
s	O
parents	O
before	O
commencing	O
combination	O
therapy	O
.	O

The	O
dose	O
of	O
miglustat	B-Medication
was	O
adjusted	B-Detailed_description
according	I-Detailed_description
to	I-Detailed_description
the	I-Detailed_description
patient	I-Detailed_description
`	I-Detailed_description
s	I-Detailed_description
body	I-Detailed_description
surface	I-Detailed_description
area	I-Detailed_description
and	O
was	O
uptitrated	O
during	O
the	O
first	O
4	O
weeks	O
with	O
the	O
following	O
scheme	O
:	O
one	O
-	O
third	O
of	O
target	O
dose	O
during	O
weeks	O
1	O
and	O
2	O
,	O
two	O
-	O
thirds	O
of	O
target	O
dose	O
during	O
weeks	O
3	O
and	O
4	O
,	O
and	O
target	O
dose	O
(	O
100	B-Dosage
mg	I-Dosage
three	I-Dosage
times	I-Dosage
daily	I-Dosage
)	O
after	O
1	O
month	O
.	O

From	O
2	O
weeks	O
before	O
starting	O
miglustat	B-Medication
therapy	O
,	O
the	O
patient	O
also	O
followed	O
specific	O
dietary	B-Therapeutic_procedure
modifications	I-Therapeutic_procedure
,	O
avoiding	B-Detailed_description
high	I-Detailed_description
intake	I-Detailed_description
of	I-Detailed_description
carbohydrate	I-Detailed_description
-	I-Detailed_description
containing	I-Detailed_description
food	I-Detailed_description
in	I-Detailed_description
single	I-Detailed_description
meals	I-Detailed_description
,	O
especially	O
foods	B-Detailed_description
high	I-Detailed_description
in	I-Detailed_description
disaccharides	I-Detailed_description
,	I-Detailed_description
such	I-Detailed_description
as	I-Detailed_description
sucrose	I-Detailed_description
and	I-Detailed_description
maltose	I-Detailed_description
,	O
to	O
ensure	O
acceptable	O
gastrointestinal	O
tolerability	O
.	O

He	O
experienced	O
mild	B-Severity
episodes	O
of	O
diarrhea	B-Sign_symptom
after	O
commencing	O
miglustat	B-Medication
therapy	O
,	O
which	O
decreased	B-Lab_value
in	I-Lab_value
frequency	I-Lab_value
/	I-Lab_value
severity	I-Lab_value
over	I-Lab_value
time	I-Lab_value
.	O

From	O
the	O
start	O
of	O
ERT	O
/	O
miglustat	O
combination	O
treatment	O
,	O
we	O
observed	O
a	O
reduction	O
in	O
splenomegaly	B-Sign_symptom
and	O
a	O
gradual	O
normalization	B-Lab_value
of	O
hematological	B-Diagnostic_procedure
values	I-Diagnostic_procedure
and	O
plasma	B-Diagnostic_procedure
angiotensin	I-Diagnostic_procedure
-	I-Diagnostic_procedure
converting	I-Diagnostic_procedure
enzyme	I-Diagnostic_procedure
activity	I-Diagnostic_procedure
(	O
Table	O
1	O
)	O
.	O

Plasma	B-Diagnostic_procedure
chitotriosidase	I-Diagnostic_procedure
was	O
evaluated	O
at	O
the	O
time	O
of	O
diagnosis	O
and	O
then	O
approximately	O
every	B-Frequency
6	I-Frequency
months	I-Frequency
during	O
follow	O
-	O
up	O
.	O

Values	O
showed	O
an	O
initial	B-Lab_value
reduction	I-Lab_value
after	B-Detailed_description
the	I-Detailed_description
start	I-Detailed_description
of	I-Detailed_description
ERT	I-Detailed_description
,	O
with	O
a	O
further	O
,	O
substantial	O
,	O
and	O
sustained	B-Lab_value
decrease	I-Lab_value
after	B-Detailed_description
commencement	I-Detailed_description
of	I-Detailed_description
miglustat	I-Detailed_description
treatment	O
(	O
Fig	O
.	O
1	O
)	O
.	O

The	O
patient	O
has	O
been	O
followed	O
according	B-Detailed_description
to	I-Detailed_description
recommended	I-Detailed_description
guidelines	I-Detailed_description
for	I-Detailed_description
GD	I-Detailed_description
,	O
which	O
specify	O
a	O
complete	O
neurological	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
,	O
clinical	O
evaluation	B-Diagnostic_procedure
of	I-Diagnostic_procedure
ocular	I-Diagnostic_procedure
movements	I-Diagnostic_procedure
,	O
and	O
psychological	B-Diagnostic_procedure
evaluations	I-Diagnostic_procedure
every	B-Frequency
6	I-Frequency
-	I-Frequency
12	I-Frequency
months	I-Frequency
[	O
10	O
]	O
.	O

After	O
5	B-Duration
years	I-Duration
of	O
combination	B-Therapeutic_procedure
therapy	I-Therapeutic_procedure
and	O
follow	O
-	O
up	O
,	O
the	O
patient	O
did	O
not	O
show	O
any	O
signs	O
of	O
neurological	B-Sign_symptom
impairment	I-Sign_symptom
.	O

As	O
of	O
February	O
2016	O
,	O
he	O
had	O
not	O
displayed	O
any	O
epileptic	B-Sign_symptom
crises	I-Sign_symptom
and	O
had	O
demonstrated	O
clinical	B-Sign_symptom
performance	I-Sign_symptom
and	O
cooperation	B-Activity
.	O

He	O
showed	O
good	B-Lab_value
muscular	B-Diagnostic_procedure
tone	I-Diagnostic_procedure
and	I-Diagnostic_procedure
trophism	I-Diagnostic_procedure
,	O
normal	B-Lab_value
reflexes	B-Diagnostic_procedure
with	O
a	O
slight	B-Severity
hyperreflexia	B-Sign_symptom
in	O
his	O
legs	B-Biological_structure
,	O
and	O
a	O
negative	B-Lab_value
Romberg	B-Diagnostic_procedure
sign	I-Diagnostic_procedure
.	O

His	O
toe	B-Diagnostic_procedure
and	I-Diagnostic_procedure
heel	I-Diagnostic_procedure
deambulation	I-Diagnostic_procedure
was	O
normal	B-Lab_value
.	O

In	O
particular	O
,	O
ocular	B-Diagnostic_procedure
evaluations	I-Diagnostic_procedure
revealed	O
no	O
evidence	O
of	O
saccadic	B-Sign_symptom
movement	I-Sign_symptom
velocity	I-Sign_symptom
reduction	I-Sign_symptom
and	O
normal	B-Lab_value
visual	B-Diagnostic_procedure
evoked	I-Diagnostic_procedure
potentials	I-Diagnostic_procedure
.	O

The	O
patient	O
`	O
s	O
auditory	B-Diagnostic_procedure
brain	I-Diagnostic_procedure
responses	I-Diagnostic_procedure
were	O
also	O
normal	B-Lab_value
.	O

In	O
addition	O
,	O
he	O
has	O
not	O
demonstrated	O
any	O
cognitive	B-Sign_symptom
impairment	I-Sign_symptom
,	O
and	O
he	O
has	O
regularly	B-Detailed_description
attended	B-Activity
school	I-Activity
with	O
good	B-Detailed_description
performance	I-Detailed_description
since	O
the	O
age	O
of	O
5	O
years	O
.	O

-DOCSTART- -X- -X- -X- O

An	O
84	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
woman	O
presented	O
to	O
a	O
local	B-Nonbiological_location
clinic	I-Nonbiological_location
with	O
dyspnea	B-Sign_symptom
on	B-Detailed_description
exertion	I-Detailed_description
and	O
left	B-Biological_structure
back	I-Biological_structure
pain	B-Sign_symptom
persisting	B-Duration
for	I-Duration
a	I-Duration
month	I-Duration
.	O

She	O
was	O
admitted	O
to	O
our	O
hospital	B-Nonbiological_location
because	O
of	O
left	B-Detailed_description
pleural	B-Sign_symptom
effusion	I-Sign_symptom
on	O
a	O
chest	B-Biological_structure
X	B-Diagnostic_procedure
-	I-Diagnostic_procedure
ray	I-Diagnostic_procedure
.	O

She	O
suffered	O
hypertension	O
and	O
dyslipidemia	O
but	O
had	O
no	O
history	O
of	O
pleural	O
tuberculosis	O
or	O
chronic	O
pyothorax	O
,	O
nor	O
a	O
smoking	O
history	O
or	O
dust	O
exposure	O
.	O

On	O
examination	B-Diagnostic_procedure
,	O
her	O
vital	B-Diagnostic_procedure
signs	I-Diagnostic_procedure
and	O
oxygen	B-Diagnostic_procedure
saturation	I-Diagnostic_procedure
were	O
normal	B-Lab_value
(	O
SpO2	B-Diagnostic_procedure
:	O
96	B-Lab_value
%	I-Lab_value
ambient	B-Detailed_description
air	I-Detailed_description
)	O
.	O

A	O
chest	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
revealed	O
a	O
mass	B-Sign_symptom
on	O
the	O
left	B-Biological_structure
side	I-Biological_structure
of	I-Biological_structure
her	I-Biological_structure
back	I-Biological_structure
with	O
pain	B-Sign_symptom
and	O
decreased	B-Sign_symptom
breathing	I-Sign_symptom
sounds	I-Sign_symptom
in	O
the	O
left	B-Biological_structure
lower	I-Biological_structure
-	I-Biological_structure
lung	I-Biological_structure
field	I-Biological_structure
.	O

The	B-Detailed_description
rest	I-Detailed_description
of	O
the	O
examination	B-Diagnostic_procedure
findings	I-Diagnostic_procedure
were	O
normal	B-Lab_value
.	O

Laboratory	B-Diagnostic_procedure
tests	I-Diagnostic_procedure
revealed	O
elevated	B-Lab_value
levels	I-Lab_value
of	O
C	B-Diagnostic_procedure
reactive	I-Diagnostic_procedure
protein	I-Diagnostic_procedure
,	O
lactate	B-Diagnostic_procedure
dehydrogenase	I-Diagnostic_procedure
(	O
LDH	B-Diagnostic_procedure
)	O
,	O
and	O
soluble	B-Diagnostic_procedure
interleukin	I-Diagnostic_procedure
-	I-Diagnostic_procedure
2	I-Diagnostic_procedure
receptor	I-Diagnostic_procedure
(	O
sIL	B-Diagnostic_procedure
-	I-Diagnostic_procedure
2R	I-Diagnostic_procedure
)	O
(	O
Table	O
1	O
)	O
.	O

A	O
chest	B-Biological_structure
X	B-Diagnostic_procedure
-	I-Diagnostic_procedure
ray	I-Diagnostic_procedure
(	O
Fig	O
.	O
1	O
)	O
showed	O
left	B-Detailed_description
pleural	B-Sign_symptom
effusion	I-Sign_symptom
with	O
mediastinal	B-Detailed_description
shift	I-Detailed_description
.	O

On	O
the	O
first	O
hospital	O
day	O
,	O
an	O
intercostal	B-Biological_structure
drainage	B-Therapeutic_procedure
tube	I-Therapeutic_procedure
was	O
inserted	O
,	O
and	O
after	O
drainage	O
,	O
chest	B-Biological_structure
computed	B-Diagnostic_procedure
tomography	I-Diagnostic_procedure
(	O
CT	B-Diagnostic_procedure
)	O
(	O
Fig	O
.	O
2	O
)	O
revealed	O
an	O
irregular	B-Detailed_description
pleural	B-Biological_structure
mass	B-Sign_symptom
invading	O
her	O
left	B-Biological_structure
chest	I-Biological_structure
wall	I-Biological_structure
with	O
rib	B-Biological_structure
destruction	B-Sign_symptom
and	O
pleural	B-Sign_symptom
effusion	I-Sign_symptom
.	O

The	O
mass	B-Sign_symptom
was	O
adjacent	B-Biological_structure
to	I-Biological_structure
the	I-Biological_structure
posterior	I-Biological_structure
mediastinum	I-Biological_structure
,	O
but	O
the	O
lateral	B-Detailed_description
side	I-Detailed_description
of	O
the	O
mass	B-Sign_symptom
was	O
thick	B-Detailed_description
and	O
invading	O
the	O
chest	B-Biological_structure
wall	I-Biological_structure
,	O
so	O
we	O
diagnosed	O
this	O
mass	B-Sign_symptom
as	O
a	O
chest	B-Disease_disorder
wall	I-Disease_disorder
tumor	I-Disease_disorder
.	O

The	O
pleural	B-Biological_structure
fluid	I-Biological_structure
was	O
serous	B-Sign_symptom
and	O
not	O
purulent	B-Sign_symptom
.	O

A	O
fluid	B-Diagnostic_procedure
analysis	I-Diagnostic_procedure
showed	O
it	O
to	O
be	O
exudative	B-Lab_value
,	O
and	O
81	B-Lab_value
%	I-Lab_value
of	I-Lab_value
the	I-Lab_value
white	I-Lab_value
blood	I-Lab_value
cells	I-Lab_value
were	I-Lab_value
lymphocytes	I-Lab_value
.	O

The	O
fluid	B-Diagnostic_procedure
culture	I-Diagnostic_procedure
was	O
negative	B-Lab_value
,	O
and	O
cytology	B-Diagnostic_procedure
did	O
not	O
show	O
any	O
evidence	O
of	O
malignancy	B-Sign_symptom
(	O
Table	O
1	O
)	O
.	O

CT	B-Detailed_description
-	I-Detailed_description
guided	I-Detailed_description
needle	B-Detailed_description
biopsy	B-Diagnostic_procedure
was	O
performed	O
.	O

The	O
histopathology	B-Diagnostic_procedure
results	O
supported	O
a	O
diagnosis	O
of	O
diffuse	B-Disease_disorder
large	I-Disease_disorder
B	I-Disease_disorder
-	I-Disease_disorder
cell	I-Disease_disorder
lymphoma	I-Disease_disorder
(	O
DLBCL	B-Disease_disorder
)	O
that	O
was	O
positive	B-Lab_value
for	O
CD10	B-Diagnostic_procedure
and	O
CD20	B-Diagnostic_procedure
but	O
negative	B-Lab_value
for	O
CD3	B-Diagnostic_procedure
and	O
CD5	B-Diagnostic_procedure
(	O
Fig	O
.	O
3	O
)	O
.	O

18	B-Diagnostic_procedure
-	I-Diagnostic_procedure
fluorodeoxyglucose	I-Diagnostic_procedure
positron	I-Diagnostic_procedure
emission	I-Diagnostic_procedure
tomography	I-Diagnostic_procedure
/	I-Diagnostic_procedure
computed	I-Diagnostic_procedure
tomography	I-Diagnostic_procedure
(	O
FDG	B-Diagnostic_procedure
-	I-Diagnostic_procedure
PET	I-Diagnostic_procedure
/	I-Diagnostic_procedure
CT	I-Diagnostic_procedure
)	O
revealed	O
high	B-Sign_symptom
FDG	I-Sign_symptom
uptake	I-Sign_symptom
in	O
the	O
left	B-Biological_structure
chest	I-Biological_structure
wall	I-Biological_structure
mass	B-Sign_symptom
without	O
any	O
other	O
uptake	O
(	O
Fig	O
.	O
4A	O
and	O
B	O
)	O
,	O
so	O
we	O
diagnosed	O
her	O
with	O
primary	B-Disease_disorder
malignant	I-Disease_disorder
lymphoma	I-Disease_disorder
originating	B-Biological_structure
from	I-Biological_structure
the	I-Biological_structure
chest	I-Biological_structure
wall	I-Biological_structure
.	O

We	O
reconfirmed	O
her	O
medical	O
history	O
,	O
and	O
she	O
never	O
had	O
either	O
tuberculous	O
pleurisy	O
or	O
pyothorax	O
.	O

Her	O
performance	B-Diagnostic_procedure
status	I-Diagnostic_procedure
(	O
PS	B-Diagnostic_procedure
)	O
was	O
3	B-Lab_value
because	O
of	O
her	O
back	B-Biological_structure
pain	B-Sign_symptom
and	O
fatigue	B-Sign_symptom
.	O

Owing	O
to	O
her	O
bad	O
PS	O
and	O
age	O
,	O
it	O
was	O
difficult	O
to	O
perform	O
an	O
operation	O
or	O
administer	O
combination	O
chemotherapy	O
with	O
Rituximab	B-Medication
,	O
so	O
low	B-Detailed_description
-	I-Detailed_description
dose	I-Detailed_description
oral	O
etoposide	B-Medication
(	O
50	B-Dosage
mg	I-Dosage
/	I-Dosage
day	I-Dosage
d1	I-Dosage
-	I-Dosage
14	I-Dosage
,	I-Dosage
q28	I-Dosage
)	O
was	O
administered	O
.	O

Her	O
pleural	B-Sign_symptom
effusion	I-Sign_symptom
disappeared	O
within	O
two	O
weeks	O
,	O
her	O
back	B-Biological_structure
pain	B-Sign_symptom
disappeared	O
,	O
and	O
her	O
PS	B-Diagnostic_procedure
improved	O
to	O
1	B-Lab_value
within	O
a	O
month	O
.	O

Chest	B-Diagnostic_procedure
CT	I-Diagnostic_procedure
performed	O
four	O
months	O
later	O
showed	O
complete	B-Lab_value
response	I-Lab_value
(	O
Fig	O
.	O
4C	O
and	O
D	O
)	O
.	O

She	O
continued	O
oral	O
chemotherapy	B-Medication
and	O
maintained	O
a	O
good	B-Lab_value
PS	B-Diagnostic_procedure
for	O
one	O
year	O
after	O
the	O
diagnosis	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
73	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
woman	O
was	O
initially	O
referred	O
19	O
months	O
prior	O
to	O
the	O
current	O
presentation	O
,	O
at	O
which	O
time	O
fluorescein	B-Detailed_description
and	O
indocyanine	B-Detailed_description
green	I-Detailed_description
angiography	B-Diagnostic_procedure
showed	O
a	O
medium	B-Detailed_description
-	I-Detailed_description
sized	I-Detailed_description
subfoveal	B-Detailed_description
classic	B-Detailed_description
CNV	B-Disease_disorder
in	O
the	O
left	B-Biological_structure
eye	I-Biological_structure
,	O
which	O
had	O
not	B-Detailed_description
been	I-Detailed_description
previously	I-Detailed_description
treated	I-Detailed_description
.	O

She	O
did	O
not	O
return	O
for	O
treatment	B-Therapeutic_procedure
until	O
the	O
current	O
presentation	O
,	O
when	O
she	O
noted	O
decreased	B-Sign_symptom
vision	I-Sign_symptom
in	O
the	O
left	B-Biological_structure
eye	I-Biological_structure
.	O

The	O
best	B-Diagnostic_procedure
-	I-Diagnostic_procedure
corrected	I-Diagnostic_procedure
visual	I-Diagnostic_procedure
acuity	I-Diagnostic_procedure
(	O
BCVA	B-Diagnostic_procedure
)	O
was	O
20	B-Lab_value
/	I-Lab_value
100	I-Lab_value
.	O

Slit	B-Diagnostic_procedure
lamp	I-Diagnostic_procedure
examination	I-Diagnostic_procedure
showed	O
a	O
small	B-Detailed_description
yellowish	B-Color
patch	B-Sign_symptom
in	O
the	O
perifoveal	B-Biological_structure
region	I-Biological_structure
and	O
retinal	B-Sign_symptom
edema	I-Sign_symptom
.	O

Structural	B-Detailed_description
OCT	B-Diagnostic_procedure
revealed	O
the	O
retinal	B-Sign_symptom
elevation	I-Sign_symptom
,	O
subretinal	B-Sign_symptom
fluid	I-Sign_symptom
and	O
a	O
hyper	B-Biological_structure
-	I-Biological_structure
reflective	I-Biological_structure
elongated	B-Sign_symptom
area	I-Sign_symptom
above	B-Biological_structure
RPE	I-Biological_structure
indicating	O
type	B-Lab_value
II	I-Lab_value
CNV	B-Disease_disorder
.	O

Anti	B-Therapeutic_procedure
-	I-Therapeutic_procedure
angiogenic	I-Therapeutic_procedure
treatment	I-Therapeutic_procedure
with	O
intravitreal	O
aflibercept	B-Medication
injections	O
were	O
administered	O
with	O
a	O
treat	B-Detailed_description
-	I-Detailed_description
and	I-Detailed_description
-	I-Detailed_description
extend	I-Detailed_description
regimen	I-Detailed_description
.	O

OCT	B-Diagnostic_procedure
angiograms	B-Detailed_description
(	O
Fig	O
.	O
1	O
)	O
showed	O
noticeable	B-Lab_value
reduction	I-Lab_value
in	O
CNV	B-Diagnostic_procedure
flow	I-Diagnostic_procedure
area	I-Diagnostic_procedure
by	O
1	O
-	O
2	O
days	O
post	O
injection	O
,	O
with	O
continued	B-Lab_value
reduction	I-Lab_value
at	O
1	O
week	O
and	O
2	O
weeks	O
.	O

CNV	B-Diagnostic_procedure
flow	I-Diagnostic_procedure
area	I-Diagnostic_procedure
and	O
vessel	B-Diagnostic_procedure
density	I-Diagnostic_procedure
were	O
reduced	B-Lab_value
,	O
probably	O
due	O
to	O
the	O
decreased	O
flow	O
or	O
temporary	O
closure	O
of	O
the	O
smaller	O
anastomoses	O
.	O

Significant	B-Severity
re	B-Lab_value
-	I-Lab_value
appearance	I-Lab_value
of	O
CNV	B-Disease_disorder
was	O
noticeable	O
at	O
4	O
weeks	O
after	O
the	O
first	O
injection	O
and	O
again	O
at	O
6	O
weeks	O
after	O
the	O
second	O
injection	O
.	O

The	O
vascular	O
pattern	O
of	O
the	O
re	B-Detailed_description
-	I-Detailed_description
enlarged	I-Detailed_description
CNV	B-Disease_disorder
(	O
Fig	O
.	O
1A	O
)	O
was	O
very	O
similar	O
to	O
the	O
initial	O
pretreatment	O
CNV	O
,	O
suggesting	O
that	O
the	O
recurrence	O
may	O
be	O
reopening	O
of	O
original	O
channels	O
rather	O
than	O
growth	O
of	O
new	O
vessels	O
.	O

Comparing	O
the	O
CNV	O
network	O
prior	O
to	O
the	O
3rd	O
injection	O
to	O
the	O
baseline	O
,	O
it	O
is	O
notable	O
that	O
there	O
were	O
fewer	O
smaller	O
channels	O
,	O
while	O
the	O
larger	O
caliber	O
channels	O
remained	O
.	O

Quantitative	O
measurements	O
from	O
OCT	B-Diagnostic_procedure
angiography	B-Detailed_description
(	O
Fig	O
.	O
2A	O
)	O
showed	O
reduction	B-Lab_value
in	O
CNV	B-Diagnostic_procedure
flow	I-Diagnostic_procedure
area	I-Diagnostic_procedure
and	O
flow	B-Diagnostic_procedure
index	I-Diagnostic_procedure
over	B-Duration
the	I-Duration
first	I-Duration
2	I-Duration
weeks	I-Duration
with	O
subsequent	O
return	O
.	O

Retinal	B-Sign_symptom
thickness	I-Sign_symptom
(	O
Fig	O
.	O
2B	O
)	O
showed	O
the	O
fluid	O
resorption	O
over	B-Duration
the	I-Duration
first	I-Duration
4	I-Duration
weeks	I-Duration
in	O
the	O
first	O
treatment	O
cycle	O
continuing	O
at	O
least	O
2	O
weeks	O
into	O
the	O
second	O
treatment	O
cycle	O
,	O
at	O
which	O
time	O
no	O
fluid	O
remained	O
(	O
Fig	O
.	O
1B	O
)	O
.	O

But	O
fluid	B-Sign_symptom
re	I-Sign_symptom
-	I-Sign_symptom
accumulated	I-Sign_symptom
under	B-Biological_structure
the	I-Biological_structure
retina	I-Biological_structure
6	O
weeks	O
after	O
the	O
2nd	O
injection	O
.	O

Visual	B-Diagnostic_procedure
acuity	I-Diagnostic_procedure
(	O
Fig	O
.	O
2B	O
)	O
continued	B-Lab_value
to	I-Lab_value
improve	I-Lab_value
over	O
the	O
3	O
treatment	O
cycles	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
73	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
man	O
who	O
had	O
been	O
transferred	O
to	O
our	O
emergency	B-Nonbiological_location
room	I-Nonbiological_location
due	O
to	O
sudden	B-Detailed_description
chest	B-Biological_structure
pain	B-Sign_symptom
was	O
diagnosed	O
with	O
ST	B-Disease_disorder
-	I-Disease_disorder
segment	I-Disease_disorder
elevation	I-Disease_disorder
myocardial	I-Disease_disorder
infarction	I-Disease_disorder
(	O
STEMI	B-Disease_disorder
)	O
.	O

He	O
had	O
no	O
coronary	O
risk	O
factors	O
except	O
for	O
a	O
history	O
of	O
smoking	O
for	O
50	O
years	O
.	O

Primary	B-Detailed_description
percutaneous	B-Biological_structure
coronary	B-Therapeutic_procedure
intervention	I-Therapeutic_procedure
was	O
performed	O
,	O
and	O
a	O
long	B-Detailed_description
,	O
string	B-Shape
-	I-Shape
shaped	I-Shape
contrast	B-Sign_symptom
defect	I-Sign_symptom
was	O
observed	O
in	O
the	O
left	B-Biological_structure
anterior	I-Biological_structure
descending	I-Biological_structure
artery	I-Biological_structure
(	O
Fig	O
.	O
1A	O
)	O
.	O

Optical	B-Diagnostic_procedure
coherence	I-Diagnostic_procedure
tomography	I-Diagnostic_procedure
(	O
OCT	B-Diagnostic_procedure
)	O
imaging	O
revealed	O
an	O
odd	B-Detailed_description
,	O
smooth	B-Texture
-	I-Texture
surfaced	I-Texture
50	B-Distance
-	I-Distance
mm	I-Distance
long	I-Distance
object	B-Sign_symptom
(	O
Fig	O
.	O
1B	O
)	O
.	O

A	O
long	B-Detailed_description
,	O
white	B-Color
object	B-Sign_symptom
which	O
looked	B-Detailed_description
like	I-Detailed_description
a	I-Detailed_description
parasitic	I-Detailed_description
worm	I-Detailed_description
was	O
retrieved	O
via	O
intracoronary	B-Therapeutic_procedure
aspiration	I-Therapeutic_procedure
and	O
revascularization	B-Therapeutic_procedure
was	O
successfully	B-Lab_value
completed	I-Lab_value
since	O
neither	O
plaque	B-Sign_symptom
rupture	I-Sign_symptom
or	O
the	O
presence	O
of	O
thrombus	B-Sign_symptom
was	O
detected	O
by	O
OCT	O
(	O
Fig	O
.	O
1C	O
)	O
.	O

On	O
the	O
eleventh	O
hospital	O
day	O
,	O
transthoracic	B-Biological_structure
echocardiography	B-Diagnostic_procedure
revealed	O
a	O
new	O
floating	B-Detailed_description
object	B-Sign_symptom
in	O
the	O
left	B-Biological_structure
atrium	I-Biological_structure
.	O

Contrast	B-Diagnostic_procedure
computed	I-Diagnostic_procedure
tomography	I-Diagnostic_procedure
revealed	O
a	O
huge	B-Detailed_description
7	B-Area
×	I-Area
6	I-Area
cm	I-Area
mass	B-Sign_symptom
that	O
was	O
recognized	O
at	O
admission	O
in	O
the	O
right	B-Biological_structure
upper	I-Biological_structure
pulmonary	I-Biological_structure
lobe	I-Biological_structure
with	O
direct	B-Detailed_description
pulmonary	I-Detailed_description
vein	I-Detailed_description
invasion	I-Detailed_description
(	O
Fig	O
.	O
1D	O
)	O
.	O

Although	O
the	O
bronchoscopic	B-Diagnostic_procedure
findings	I-Diagnostic_procedure
were	O
negative	O
for	O
a	O
lung	B-Sign_symptom
tumor	I-Sign_symptom
,	O
a	O
histopathologic	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
of	O
the	O
aspirated	B-Detailed_description
coronary	B-Biological_structure
object	O
revealed	O
pleomorphic	B-Detailed_description
lung	B-Biological_structure
carcinoma	B-Disease_disorder
(	O
Fig	O
.	O
2	O
)	O
.	O

The	O
patient	O
was	O
diagnosed	O
with	O
STEMI	B-Disease_disorder
due	O
to	O
coronary	B-Biological_structure
embolization	B-Sign_symptom
associated	O
with	O
lung	B-Biological_structure
carcinoma	B-Disease_disorder
.	O

Brain	B-Biological_structure
MRI	B-Diagnostic_procedure
revealed	O
that	O
the	O
patient	O
had	O
an	O
asymptomatic	B-Detailed_description
cerebral	B-Biological_structure
infarction	B-Sign_symptom
in	O
the	O
right	B-Biological_structure
frontal	I-Biological_structure
lobe	I-Biological_structure
and	O
a	O
small	B-Detailed_description
parietal	B-Biological_structure
lobe	I-Biological_structure
lesion	B-Sign_symptom
was	O
diagnosed	O
to	O
be	O
metastasis	B-Sign_symptom
.	O

Given	O
all	O
these	O
observations	O
,	O
he	O
was	O
diagnosed	O
with	O
right	B-Biological_structure
lung	I-Biological_structure
carcinoma	B-Disease_disorder
,	O
stage	B-Detailed_description
IV	I-Detailed_description
(	O
c	B-Detailed_description
-	I-Detailed_description
T2bN2M1b	I-Detailed_description
)	O
.	O

He	O
was	O
treated	O
according	O
to	O
the	O
chemotherapy	B-Medication
regimens	O
(	O
carboplatin	B-Medication
&	O
paclitaxel	B-Medication
)	O
known	O
to	O
be	O
effective	O
for	O
the	O
treatment	O
of	O
advanced	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
.	O

He	O
responded	O
to	O
the	O
treatment	O
and	O
showed	O
a	O
good	B-Lab_value
clinical	B-Diagnostic_procedure
course	I-Diagnostic_procedure
afterwards	O
(	O
Fig	O
.	O
3	O
)	O
.	O

Chemotherapy	B-Medication
with	O
a	O
total	O
of	O
9	B-Dosage
cycles	I-Dosage
of	O
the	O
same	O
regimen	O
was	O
used	O
and	O
the	O
carcinoma	B-Diagnostic_procedure
progression	I-Diagnostic_procedure
was	O
suppressed	B-Lab_value
.	O

He	O
has	O
been	O
doing	B-Sign_symptom
well	I-Sign_symptom
for	O
more	B-Duration
than	I-Duration
two	I-Duration
years	I-Duration
of	O
PCI	B-Therapeutic_procedure
and	O
has	O
been	O
followed	O
-	O
up	O
regularly	B-Detailed_description
.	O

-DOCSTART- -X- -X- -X- O

We	O
report	O
the	O
case	O
of	O
a	O
68	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
female	O
with	O
no	O
past	O
medical	O
history	O
,	O
presented	O
with	O
an	O
upper	B-Biological_structure
gastrointestinal	I-Biological_structure
bleeding	B-Sign_symptom
and	O
pain	B-Sign_symptom
in	O
left	B-Biological_structure
upper	I-Biological_structure
abdomen	I-Biological_structure
.	O

Physical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
found	O
a	O
splenomegaly	B-Sign_symptom
and	O
signs	O
of	O
portosystemic	B-Disease_disorder
collateral	I-Disease_disorder
formation	I-Disease_disorder
including	O
abdominal	B-Biological_structure
wall	I-Biological_structure
dilated	B-Sign_symptom
veins	I-Sign_symptom
and	O
rectal	B-Biological_structure
haemorrhoids	B-Sign_symptom
.	O

No	O
biological	B-Sign_symptom
abnormalities	I-Sign_symptom
were	O
noted	O
besides	O
those	O
due	O
to	O
hypersplenism	B-Disease_disorder
(	O
anaemia	B-Sign_symptom
and	O
thrombocytopenia	B-Sign_symptom
)	O
.	O

The	O
patient	O
underwent	O
upper	B-Biological_structure
gastrointestinal	I-Biological_structure
endoscopy	B-Diagnostic_procedure
that	O
showed	O
stage	B-Detailed_description
III	I-Detailed_description
oesophageal	B-Biological_structure
varices	B-Sign_symptom
with	O
portal	B-Disease_disorder
hypertensive	I-Disease_disorder
gastropathy	I-Disease_disorder
and	O
red	B-Sign_symptom
signs	I-Sign_symptom
.	O

Ultrasonography	B-Diagnostic_procedure
revealed	O
a	O
fusiform	B-Sign_symptom
dilatation	I-Sign_symptom
of	O
the	O
portal	B-Biological_structure
bifurcation	I-Biological_structure
measuring	O
40	B-Distance
mm	I-Distance
in	O
diameter	O
with	O
dilated	B-Detailed_description
branches	I-Detailed_description
;	O
no	O
signs	B-Sign_symptom
of	I-Sign_symptom
portal	I-Sign_symptom
thrombosis	I-Sign_symptom
were	O
detected	O
(	O
Figure	O
1	O
)	O
.	O

The	O
portal	B-Biological_structure
Doppler	B-Diagnostic_procedure
study	I-Diagnostic_procedure
showed	O
a	O
normal	B-Lab_value
hepatopetal	I-Lab_value
flow	I-Lab_value
.	O

Other	B-Sign_symptom
signs	I-Sign_symptom
of	I-Sign_symptom
portal	I-Sign_symptom
hypertension	I-Sign_symptom
were	O
found	O
,	O
including	O
splenomegaly	B-Sign_symptom
,	O
repermeation	B-Sign_symptom
of	O
the	O
umbilical	B-Biological_structure
vein	I-Biological_structure
and	O
a	O
splenorenal	B-Biological_structure
collateral	B-Sign_symptom
circulation	I-Sign_symptom
.	O

A	O
complementary	O
angio	B-Biological_structure
-	O
CT	B-Diagnostic_procedure
allowed	O
a	O
better	O
assessment	O
of	O
the	O
portal	O
system	O
that	O
contained	O
some	O
thin	B-Sign_symptom
calcifications	I-Sign_symptom
in	O
the	O
aneurysmal	B-Biological_structure
wall	I-Biological_structure
and	O
the	O
main	B-Biological_structure
portal	I-Biological_structure
trunk	I-Biological_structure
(	O
Figure	O
2	O
,	O
Figure	O
3	O
,	O
Figure	O
4	O
)	O
.	O

Other	B-Sign_symptom
signs	I-Sign_symptom
of	I-Sign_symptom
portal	I-Sign_symptom
hypertension	I-Sign_symptom
were	O
noted	O
such	O
as	O
oesophageal	B-Biological_structure
and	O
gastric	B-Biological_structure
varices	B-Sign_symptom
,	O
parietal	B-Biological_structure
collateral	B-Sign_symptom
circulation	I-Sign_symptom
associated	O
to	O
ultrasonography	O
findings	O
.	O

Liver	B-Disease_disorder
cirrhosis	I-Disease_disorder
was	O
confirmed	O
by	O
transcient	B-Diagnostic_procedure
elastometry	I-Diagnostic_procedure
and	O
biopsy	B-Diagnostic_procedure
.	O

-DOCSTART- -X- -X- -X- O

This	O
young	B-Age
boy	O
is	O
the	O
first	O
child	O
of	O
healthy	B-Detailed_description
non	B-Detailed_description
-	I-Detailed_description
consanguineous	I-Detailed_description
,	O
white	O
British	O
parents	O
.	O

He	O
was	O
born	O
at	B-Detailed_description
term	I-Detailed_description
following	O
an	O
uneventful	B-Detailed_description
pregnancy	I-Detailed_description
weighing	O
3132	B-Weight
g	I-Weight
(	O
9th	O
-	O
25th	O
centile	O
)	O
.	O

Early	B-Diagnostic_procedure
development	I-Diagnostic_procedure
was	O
thought	O
to	O
be	O
normal	B-Lab_value
.	O

At	O
approximately	O
6	O
months	O
of	O
age	O
he	O
developed	O
tonic	B-Detailed_description
upward	I-Detailed_description
eye	B-Sign_symptom
deviation	I-Sign_symptom
associated	O
with	O
flexion	B-Sign_symptom
of	O
his	O
arms	B-Biological_structure
and	O
neck	B-Biological_structure
consistent	O
with	O
infantile	B-Disease_disorder
spasms	I-Disease_disorder
.	O

An	O
electroencephalograph	B-Diagnostic_procedure
(	O
EEG	B-Diagnostic_procedure
)	O
at	O
this	O
time	O
was	O
grossly	B-Lab_value
abnormal	I-Lab_value
(	O
hypsarrhythmia	B-Sign_symptom
)	O
and	O
strongly	O
supported	O
a	O
diagnosis	O
of	O
West	B-Disease_disorder
Syndrome	I-Disease_disorder
.	O

Cranial	B-Biological_structure
MRI	B-Diagnostic_procedure
was	O
reported	O
as	O
normal	B-Lab_value
.	O

Prednisolone	B-Medication
was	O
prescribed	O
and	O
treated	O
the	O
seizures	B-Sign_symptom
effectively	O
.	O

Steroids	B-Medication
were	O
weaned	O
over	B-Duration
6	I-Duration
weeks	I-Duration
and	O
he	O
remained	O
seizure	B-Sign_symptom
free	O
for	O
a	O
further	B-Duration
6	I-Duration
months	I-Duration
.	O

By	O
the	O
age	O
of	O
1	O
year	O
,	O
it	O
was	O
apparent	O
that	O
his	O
early	O
developmental	B-Diagnostic_procedure
progress	I-Diagnostic_procedure
was	O
not	B-Lab_value
being	I-Lab_value
maintained	I-Lab_value
and	O
that	O
he	O
was	O
functioning	O
at	O
the	O
6	B-Lab_value
-	I-Lab_value
8	I-Lab_value
month	I-Lab_value
developmental	B-Diagnostic_procedure
stage	I-Diagnostic_procedure
.	O

Seizures	B-Sign_symptom
returned	O
shortly	O
after	O
his	O
first	O
birthday	O
and	O
were	O
prolonged	B-Detailed_description
,	O
frequent	B-Detailed_description
and	O
on	B-Detailed_description
occasion	I-Detailed_description
focal	I-Detailed_description
,	O
involving	O
his	O
right	B-Biological_structure
arm	I-Biological_structure
,	O
leg	B-Biological_structure
and	O
right	B-Biological_structure
side	I-Biological_structure
of	I-Biological_structure
face	I-Biological_structure
.	O

Clonazepam	B-Medication
briefly	O
improved	O
seizure	B-Sign_symptom
frequency	O
,	O
but	O
subsequently	O
his	O
epilepsy	B-Disease_disorder
has	O
proved	O
refractory	B-Detailed_description
to	I-Detailed_description
various	I-Detailed_description
combinations	I-Detailed_description
of	I-Detailed_description
anticonvulsant	I-Detailed_description
therapy	I-Detailed_description
.	O

Prolonged	B-Detailed_description
seizures	B-Sign_symptom
of	O
more	B-Detailed_description
than	I-Detailed_description
60	I-Detailed_description
min	I-Detailed_description
have	O
been	O
associated	O
with	O
a	O
stepwise	B-Lab_value
regression	I-Lab_value
in	O
his	O
neurodevelopment	B-Diagnostic_procedure
.	O

Seizure	B-Sign_symptom
semiology	O
is	O
now	O
predominantly	O
one	O
of	O
epilepsia	B-Disease_disorder
partialis	I-Disease_disorder
continua	I-Disease_disorder
involving	O
the	O
right	B-Biological_structure
side	I-Biological_structure
of	I-Biological_structure
his	I-Biological_structure
face	I-Biological_structure
,	O
right	B-Biological_structure
arm	I-Biological_structure
and	O
right	B-Biological_structure
leg	I-Biological_structure
.	O

The	O
development	O
of	O
focal	B-Detailed_description
seizures	B-Sign_symptom
and	O
the	O
progressive	B-Detailed_description
nature	O
of	O
the	O
condition	O
prompted	O
a	O
second	O
cranial	B-Biological_structure
MRI	B-Diagnostic_procedure
at	O
the	O
age	O
of	O
2	O
years	O
6	O
months	O
.	O

By	O
contrast	O
with	O
the	O
previous	O
scan	O
,	O
this	O
MRI	B-Diagnostic_procedure
revealed	O
symmetrical	B-Detailed_description
subcortical	B-Biological_structure
white	I-Biological_structure
matter	I-Biological_structure
lesions	B-Sign_symptom
(	O
Fig	O
.	O
1A	O
)	O
with	O
thinning	B-Sign_symptom
of	O
the	O
anterior	B-Biological_structure
and	I-Biological_structure
genu	I-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
corpus	I-Biological_structure
callosum	I-Biological_structure
(	O
Fig	O
.	O
1B	O
)	O
.	O

On	O
examination	B-Diagnostic_procedure
,	O
the	O
patient	O
had	O
small	B-Detailed_description
,	O
round	B-Shape
,	O
anteriorly	B-Detailed_description
rotated	I-Detailed_description
ears	B-Biological_structure
and	O
a	O
broad	B-Detailed_description
nasal	B-Biological_structure
root	I-Biological_structure
.	O

He	O
demonstrated	O
no	B-Lab_value
visual	B-Diagnostic_procedure
awareness	I-Diagnostic_procedure
but	O
startled	B-Sign_symptom
to	I-Sign_symptom
loud	I-Sign_symptom
noise	I-Sign_symptom
.	O

Tone	B-Diagnostic_procedure
was	O
increased	B-Lab_value
in	O
all	B-Biological_structure
4	I-Biological_structure
limbs	I-Biological_structure
with	O
internal	B-Sign_symptom
rotation	I-Sign_symptom
of	O
both	B-Biological_structure
legs	I-Biological_structure
at	I-Biological_structure
the	I-Biological_structure
hips	I-Biological_structure
.	O

Reflexes	B-Diagnostic_procedure
were	O
pathologically	B-Lab_value
brisk	I-Lab_value
.	O

Brief	B-Detailed_description
myoclonic	B-Sign_symptom
jerks	I-Sign_symptom
were	O
evident	O
throughout	O
the	O
examination	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
33	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
Moroccan	O
man	O
with	O
a	O
5	B-Duration
-	I-Duration
month	I-Duration
history	O
of	O
recurring	B-Detailed_description
sinusitis	B-Disease_disorder
presented	O
with	O
temperature	B-Sign_symptom
,	O
myalgia	B-Sign_symptom
,	O
cough	B-Sign_symptom
,	O
and	O
hemoptysis	B-Sign_symptom
.	O

Thoracic	B-Biological_structure
physical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
revealed	O
reduced	B-Lab_value
vesicular	B-Diagnostic_procedure
murmur	I-Diagnostic_procedure
,	O
and	O
chest	B-Biological_structure
X	B-Diagnostic_procedure
-	I-Diagnostic_procedure
ray	I-Diagnostic_procedure
showed	O
bilateral	B-Detailed_description
diffuse	B-Detailed_description
alveolar	B-Biological_structure
infiltrates	B-Sign_symptom
.	O

Laboratory	B-Diagnostic_procedure
analyses	I-Diagnostic_procedure
showed	O
elevation	B-Lab_value
of	O
acute	B-Diagnostic_procedure
-	I-Diagnostic_procedure
phase	I-Diagnostic_procedure
proteins	I-Diagnostic_procedure
(	O
CRP	B-Diagnostic_procedure
26	B-Lab_value
mg	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
)	O
and	O
creatinine	B-Diagnostic_procedure
(	O
1	B-Lab_value
.	I-Lab_value
2	I-Lab_value
mg	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
)	O
with	O
nonnephrotic	B-Detailed_description
proteinuria	B-Sign_symptom
and	O
microscopic	B-Detailed_description
glomerular	B-Detailed_description
hematuria	B-Sign_symptom
.	O

An	O
antibiotic	B-Medication
therapy	I-Medication
for	O
community	B-Detailed_description
acquired	I-Detailed_description
and	O
atypical	B-Detailed_description
pneumoniae	B-Disease_disorder
with	O
levofloxacin	B-Medication
500	B-Dosage
mg	I-Dosage
daily	I-Dosage
iv	O
was	O
established	O
,	O
but	O
on	O
the	O
3rd	O
day	O
from	O
admission	O
the	O
patient	O
developed	O
respiratory	B-Disease_disorder
failure	I-Disease_disorder
unresponsive	O
to	O
noninvasive	B-Detailed_description
ventilation	B-Therapeutic_procedure
and	O
had	O
to	O
be	O
intubated	B-Therapeutic_procedure
.	O

White	B-Color
lung	B-Biological_structure
with	O
consolidations	B-Sign_symptom
and	O
ground	B-Sign_symptom
glass	I-Sign_symptom
areas	I-Sign_symptom
at	O
computed	B-Diagnostic_procedure
tomography	I-Diagnostic_procedure
scan	O
(	O
Fig	O
.	O
1	O
)	O
,	O
diffuse	B-Detailed_description
airways	B-Biological_structure
bleeding	B-Sign_symptom
at	O
fiberoptic	B-Detailed_description
bronchoscopy	B-Diagnostic_procedure
,	O
mild	B-Severity
normocytic	B-Detailed_description
anemia	B-Diagnostic_procedure
(	O
9	B-Lab_value
g	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
)	O
,	O
and	O
ANCA	B-Diagnostic_procedure
-	I-Diagnostic_procedure
PR3	I-Diagnostic_procedure
positivity	B-Lab_value
(	O
18	B-Lab_value
.	I-Lab_value
9	I-Lab_value
U	I-Lab_value
/	I-Lab_value
mL	I-Lab_value
)	O
were	O
consistent	O
with	O
the	O
diagnosis	O
of	O
GPA	B-Disease_disorder
.	O

Despite	O
maximal	B-Detailed_description
ventilatory	B-Therapeutic_procedure
support	I-Therapeutic_procedure
,	O
gas	B-Diagnostic_procedure
exchange	I-Diagnostic_procedure
did	B-Lab_value
not	I-Lab_value
improve	I-Lab_value
(	O
pH	B-Diagnostic_procedure
7	B-Lab_value
.	I-Lab_value
33	I-Lab_value
,	O
PaO2	B-Diagnostic_procedure
71	B-Lab_value
mm	I-Lab_value
Hg	I-Lab_value
,	O
PaCO2	B-Diagnostic_procedure
51	B-Lab_value
mm	I-Lab_value
Hg	I-Lab_value
,	O
HCO3	B-Diagnostic_procedure
-	O
25	B-Lab_value
mmol	I-Lab_value
/	I-Lab_value
L	I-Lab_value
,	O
SaO2	B-Diagnostic_procedure
94	B-Lab_value
%	I-Lab_value
)	O
requiring	O
extracorporeal	B-Therapeutic_procedure
membrane	I-Therapeutic_procedure
oxygenation	I-Therapeutic_procedure
(	O
ECMO	B-Therapeutic_procedure
)	O
.	O

Treatment	O
with	O
high	B-Dosage
-	I-Dosage
dose	I-Dosage
methylprednisolone	B-Medication
(	O
1	B-Dosage
g	I-Dosage
daily	I-Dosage
for	O
3	B-Duration
days	I-Duration
and	O
1	B-Dosage
mg	I-Dosage
/	I-Dosage
kg	I-Dosage
daily	I-Dosage
thereafter	O
)	O
,	O
cyclophosphamide	B-Medication
(	O
1	B-Dosage
.	I-Dosage
2	I-Dosage
g	I-Dosage
/	I-Dosage
pulse	I-Dosage
every	I-Dosage
2	I-Dosage
weeks	I-Dosage
for	I-Dosage
the	I-Dosage
1st	I-Dosage
3	I-Dosage
pulses	I-Dosage
,	O
followed	O
by	O
infusions	O
every	B-Dosage
3	I-Dosage
weeks	I-Dosage
for	I-Dosage
the	I-Dosage
next	I-Dosage
2	I-Dosage
pulses	I-Dosage
)	O
,	O
and	O
plasma	B-Therapeutic_procedure
exchange	I-Therapeutic_procedure
(	O
PE	B-Therapeutic_procedure
)	O
,	O
according	O
to	O
European	B-Detailed_description
vasculitis	I-Detailed_description
study	I-Detailed_description
group	I-Detailed_description
recommendations	I-Detailed_description
,	O
[	O
4	O
]	O
was	O
immediately	O
started	O
with	O
respiratory	B-Diagnostic_procedure
improvement	B-Lab_value
that	O
allowed	O
ECMO	B-Therapeutic_procedure
and	O
orotracheal	B-Therapeutic_procedure
tube	I-Therapeutic_procedure
withdrawal	O
and	O
subsequent	O
discharge	O
from	O
intensive	B-Nonbiological_location
care	I-Nonbiological_location
unit	I-Nonbiological_location
.	O

After	O
9	O
days	O
from	O
the	O
beginning	O
of	O
treatment	O
ANCA	B-Diagnostic_procedure
-	I-Diagnostic_procedure
PR3	I-Diagnostic_procedure
levels	O
normalized	B-Lab_value
(	O
3	B-Lab_value
U	I-Lab_value
/	I-Lab_value
mL	I-Lab_value
)	O
.	O

Two	O
months	O
later	O
,	O
after	O
the	O
5th	B-Detailed_description
bolus	I-Detailed_description
of	O
cyclophosphamide	B-Medication
and	O
with	O
prednisone	B-Medication
0	B-Dosage
.	I-Dosage
3	I-Dosage
mg	I-Dosage
/	I-Dosage
kg	I-Dosage
/	I-Dosage
day	I-Dosage
,	O
the	O
patient	O
complained	O
arthromyalgia	B-Sign_symptom
and	O
testicular	B-Biological_structure
pain	B-Sign_symptom
with	O
edema	B-Sign_symptom
,	O
cough	B-Sign_symptom
,	O
and	O
shortness	B-Sign_symptom
of	I-Sign_symptom
breath	I-Sign_symptom
:	O
laboratory	B-Diagnostic_procedure
data	I-Diagnostic_procedure
showed	O
worsening	B-Lab_value
of	O
renal	B-Diagnostic_procedure
function	I-Diagnostic_procedure
,	O
mild	B-Severity
anemia	B-Sign_symptom
,	O
and	O
hypoxemia	B-Sign_symptom
(	O
PaO2	B-Diagnostic_procedure
61	B-Lab_value
mm	I-Lab_value
Hg	I-Lab_value
)	O
.	O

Epididymitis	B-Disease_disorder
was	O
confirmed	O
by	O
ultrasound	B-Diagnostic_procedure
.	O

Because	O
of	O
rapidly	B-Detailed_description
progressive	I-Detailed_description
renal	B-Disease_disorder
failure	I-Disease_disorder
(	O
estimated	O
glomerular	B-Diagnostic_procedure
filtration	I-Diagnostic_procedure
rate	I-Diagnostic_procedure
35	B-Lab_value
mL	I-Lab_value
/	I-Lab_value
min	I-Lab_value
)	O
renal	B-Biological_structure
biopsy	B-Diagnostic_procedure
was	O
performed	O
and	O
showed	O
prominent	B-Severity
intracapillary	B-Biological_structure
and	O
extracapillary	B-Biological_structure
proliferation	B-Sign_symptom
,	O
with	O
the	O
formation	O
of	O
some	O
fibrocellular	B-Sign_symptom
crescents	I-Sign_symptom
and	O
focal	B-Detailed_description
capillary	B-Biological_structure
necrosis	B-Sign_symptom
(	O
Fig	O
.	O
2	O
)	O
.	O

Lung	B-Biological_structure
computed	B-Diagnostic_procedure
tomography	I-Diagnostic_procedure
-	O
scan	O
and	O
fiberoptic	B-Detailed_description
bronchoscopy	B-Diagnostic_procedure
also	O
confirmed	O
alveolar	B-Biological_structure
hemorrhage	B-Sign_symptom
relapse	B-Detailed_description
.	O

Treatment	O
with	O
high	B-Dosage
-	I-Dosage
dose	I-Dosage
methylprednisolone	B-Medication
(	O
1	B-Dosage
g	I-Dosage
daily	I-Dosage
for	O
3	B-Duration
consecutive	I-Duration
days	I-Duration
)	O
and	O
rituximab	B-Medication
(	O
375	B-Dosage
mg	I-Dosage
/	I-Dosage
m2	I-Dosage
weekly	I-Dosage
for	O
4	B-Duration
weeks	I-Duration
)	O
was	O
started	O
with	O
rapid	O
resolution	O
of	O
urologic	B-Biological_structure
and	O
pulmonary	B-Biological_structure
involvement	B-Sign_symptom
but	O
delayed	B-Detailed_description
and	O
partial	B-Lab_value
improvement	I-Lab_value
of	O
renal	B-Diagnostic_procedure
function	I-Diagnostic_procedure
.	O

At	O
a	O
1	O
-	O
year	O
follow	O
-	O
up	O
,	O
the	O
patient	O
is	O
alive	B-Sign_symptom
and	O
under	O
treatment	O
with	O
azathioprine	B-Medication
(	O
150	B-Dosage
mg	I-Dosage
daily	I-Dosage
)	O
and	O
prednisone	B-Medication
(	O
15	B-Dosage
mg	I-Dosage
daily	I-Dosage
)	O
.	O

Renal	B-Diagnostic_procedure
function	I-Diagnostic_procedure
has	O
markedly	B-Lab_value
improved	I-Lab_value
(	O
estimated	O
glomerular	B-Diagnostic_procedure
filtration	I-Diagnostic_procedure
rate	I-Diagnostic_procedure
94	B-Lab_value
mL	I-Lab_value
/	I-Lab_value
min	I-Lab_value
)	O
same	O
as	O
gas	B-Diagnostic_procedure
-	I-Diagnostic_procedure
exchange	I-Diagnostic_procedure
(	O
pH	B-Diagnostic_procedure
7	B-Lab_value
.	I-Lab_value
42	I-Lab_value
,	O
PaO2	B-Diagnostic_procedure
86	B-Lab_value
mm	I-Lab_value
Hg	I-Lab_value
,	O
PaCO2	B-Diagnostic_procedure
36	B-Lab_value
mm	I-Lab_value
Hg	I-Lab_value
,	O
HCO3	B-Diagnostic_procedure
-	O
23	B-Lab_value
mmol	I-Lab_value
/	I-Lab_value
L	I-Lab_value
,	O
SaO2	B-Diagnostic_procedure
95	B-Lab_value
%	I-Lab_value
)	O
.	O

The	O
patient	O
signed	O
institutional	O
informed	O
consent	O
form	O
at	O
the	O
time	O
of	O
admission	O
to	O
hospitalization	O
.	O

An	O
approval	O
by	O
ethics	O
committee	O
was	O
not	O
necessary	O
because	O
of	O
the	O
routine	O
health	O
care	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
21	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
male	O
presented	O
with	O
a	O
2	B-Duration
-	I-Duration
year	I-Duration
history	O
of	O
progressive	B-Detailed_description
shortness	B-Sign_symptom
of	I-Sign_symptom
breath	I-Sign_symptom
on	O
exertion	B-Detailed_description
and	O
dry	B-Sign_symptom
cough	I-Sign_symptom
.	O

At	O
physical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
,	O
auscultation	B-Diagnostic_procedure
of	O
the	O
lungs	B-Biological_structure
has	O
revealed	O
random	B-Detailed_description
wheezes	B-Sign_symptom
and	O
coarse	B-Sign_symptom
crackles	I-Sign_symptom
.	O

Cardiac	B-Biological_structure
auscultation	B-Diagnostic_procedure
was	O
normal	O
,	O
and	O
no	O
cyanosis	B-Sign_symptom
or	O
peripheral	B-Sign_symptom
edema	I-Sign_symptom
was	O
observed	O
.	O

There	O
was	O
no	O
history	O
of	O
smoking	O
or	O
previous	O
known	O
pulmonary	B-Disease_disorder
disease	I-Disease_disorder
.	O

On	O
routine	B-Detailed_description
blood	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
,	O
blood	B-Diagnostic_procedure
counts	I-Diagnostic_procedure
and	O
serum	B-Diagnostic_procedure
chemistries	I-Diagnostic_procedure
were	O
found	O
to	O
be	O
normal	B-Lab_value
.	O

Arterial	B-Diagnostic_procedure
blood	I-Diagnostic_procedure
gas	I-Diagnostic_procedure
analysis	I-Diagnostic_procedure
and	O
echocardiography	B-Diagnostic_procedure
showed	O
no	B-Lab_value
important	I-Lab_value
abnormalities	I-Lab_value
.	O

Pulmonary	B-Diagnostic_procedure
function	I-Diagnostic_procedure
tests	I-Diagnostic_procedure
(	O
PFT	B-Diagnostic_procedure
)	O
showed	O
a	O
mild	B-Severity
restrictive	B-Sign_symptom
ventilatory	I-Sign_symptom
defect	I-Sign_symptom
,	O
with	O
a	O
reduced	B-Lab_value
total	B-Diagnostic_procedure
lung	I-Diagnostic_procedure
capacity	I-Diagnostic_procedure
of	O
79	B-Lab_value
%	I-Lab_value
(	O
5	B-Lab_value
.	I-Lab_value
94	I-Lab_value
L	I-Lab_value
)	O
,	O
forced	B-Diagnostic_procedure
vital	I-Diagnostic_procedure
capacity	I-Diagnostic_procedure
of	O
80	B-Lab_value
%	I-Lab_value
(	O
4	B-Lab_value
.	I-Lab_value
18	I-Lab_value
L	I-Lab_value
)	O
and	O
a	O
forced	B-Diagnostic_procedure
expiratory	I-Diagnostic_procedure
volume	I-Diagnostic_procedure
in	I-Diagnostic_procedure
one	I-Diagnostic_procedure
second	I-Diagnostic_procedure
of	O
83	B-Lab_value
%	I-Lab_value
(	O
3	B-Lab_value
.	I-Lab_value
72	I-Lab_value
L	I-Lab_value
)	O
.	O

The	O
sputum	B-Biological_structure
was	O
negative	B-Lab_value
for	O
acid	B-Diagnostic_procedure
-	I-Diagnostic_procedure
alcohol	I-Diagnostic_procedure
resistant	I-Diagnostic_procedure
bacillus	I-Diagnostic_procedure
and	O
human	B-Diagnostic_procedure
immunodeficiency	I-Diagnostic_procedure
virus	I-Diagnostic_procedure
testing	I-Diagnostic_procedure
was	O
negative	B-Lab_value
as	O
well	O
.	O

The	O
chest	B-Diagnostic_procedure
plain	I-Diagnostic_procedure
films	I-Diagnostic_procedure
revealed	O
a	O
diffuse	B-Detailed_description
symmetric	B-Detailed_description
dense	B-Texture
bilateral	B-Biological_structure
micronodular	B-Sign_symptom
pattern	I-Sign_symptom
(	O
Figure	O
1	O
)	O
.	O

Based	O
on	O
this	O
finding	O
,	O
HRCT	B-Diagnostic_procedure
scan	I-Diagnostic_procedure
was	O
obtained	O
,	O
revealing	O
diffuse	O
ground	B-Sign_symptom
glass	I-Sign_symptom
attenuation	I-Sign_symptom
and	O
septal	B-Sign_symptom
thickening	I-Sign_symptom
,	O
more	O
pronounced	O
in	O
lower	B-Biological_structure
pulmonary	I-Biological_structure
regions	I-Biological_structure
,	O
with	O
calcifications	B-Sign_symptom
along	O
the	O
interlobar	B-Biological_structure
septa	I-Biological_structure
and	O
subpleural	B-Biological_structure
regions	I-Biological_structure
.	O

Subpleural	B-Biological_structure
cysts	B-Sign_symptom
were	O
also	O
noticed	O
(	O
Figure	O
2	O
)	O
.	O

The	O
patient	O
underwent	O
a	O
fiberoptic	B-Diagnostic_procedure
bronchoscopy	I-Diagnostic_procedure
with	O
bronchoalveolar	B-Diagnostic_procedure
lavage	I-Diagnostic_procedure
and	O
transbronchial	B-Biological_structure
lung	B-Biological_structure
biopsy	B-Diagnostic_procedure
.	O

The	O
lavage	B-Biological_structure
fluid	I-Biological_structure
was	O
negative	B-Lab_value
for	O
tuberculosis	B-Diagnostic_procedure
or	O
fungi	B-Diagnostic_procedure
.	O

Microliths	B-Sign_symptom
were	O
not	O
found	O
.	O

Histology	B-Diagnostic_procedure
revealed	O
round	B-Shape
,	O
concentrically	B-Detailed_description
laminated	I-Detailed_description
microliths	B-Sign_symptom
in	O
the	O
alveoli	B-Biological_structure
associated	O
with	O
slightly	B-Severity
thickened	B-Sign_symptom
interstitial	I-Sign_symptom
septa	I-Sign_symptom
,	O
consistent	O
with	O
the	O
diagnosis	O
of	O
PAM	B-Disease_disorder
.	O

-DOCSTART- -X- -X- -X- O

A	O
64	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
man	O
was	O
admitted	O
to	O
the	O
Department	B-Nonbiological_location
of	I-Nonbiological_location
Gastroenterology	I-Nonbiological_location
of	O
the	O
Affiliated	B-Nonbiological_location
Hospital	I-Nonbiological_location
of	I-Nonbiological_location
Qingdao	I-Nonbiological_location
University	I-Nonbiological_location
Medical	I-Nonbiological_location
College	I-Nonbiological_location
(	I-Nonbiological_location
Qingdao	I-Nonbiological_location
,	I-Nonbiological_location
China	I-Nonbiological_location
)	I-Nonbiological_location
due	O
to	O
epigastric	B-Biological_structure
pains	B-Sign_symptom
.	O

Physical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
revealed	O
no	O
palpable	O
mass	B-Sign_symptom
,	O
lymphadenopathy	B-Sign_symptom
,	O
or	O
organomegaly	B-Sign_symptom
.	O

On	O
endoscopy	B-Diagnostic_procedure
,	O
several	B-Detailed_description
submucosal	B-Biological_structure
lesions	B-Sign_symptom
were	O
identified	O
in	O
the	O
gastric	B-Biological_structure
antrum	I-Biological_structure
and	O
the	O
duodenal	B-Biological_structure
bulb	I-Biological_structure
(	O
Fig	O
.	O
1	O
)	O
.	O

Endoscopic	B-Diagnostic_procedure
ultrasonography	I-Diagnostic_procedure
(	O
EUS	B-Diagnostic_procedure
)	O
(	O
OLYMPUS	B-Detailed_description
EUS	I-Detailed_description
EU	I-Detailed_description
-	I-Detailed_description
ME2	I-Detailed_description
,	O
Miniprobe	B-Detailed_description
sonography	I-Detailed_description
)	O
demonstrated	O
that	O
the	O
lesions	B-Sign_symptom
were	O
almost	B-Distance
0	I-Distance
.	I-Distance
5	I-Distance
-	I-Distance
cm	I-Distance
homogeneously	O
hypoechoic	B-Detailed_description
neoplasms	B-Sign_symptom
originating	O
from	O
the	O
submucous	B-Biological_structure
layer	I-Biological_structure
(	O
Fig	O
.	O
2	O
)	O
and	O
the	O
initial	O
diagnosis	O
was	O
digestive	B-Biological_structure
neuroendocrine	B-Disease_disorder
tumors	I-Disease_disorder
.	O

Computed	B-Diagnostic_procedure
tomography	I-Diagnostic_procedure
revealed	O
enlarged	B-Sign_symptom
lymph	I-Sign_symptom
nodes	I-Sign_symptom
in	O
multiple	O
regions	O
(	O
mediastinal	B-Biological_structure
,	O
retroperitoneal	B-Biological_structure
,	O
mesenteric	B-Biological_structure
,	O
and	O
inguinal	B-Biological_structure
)	O
and	O
intracavitary	B-Detailed_description
nodules	B-Sign_symptom
in	O
the	O
duodenum	B-Biological_structure
.	O

To	O
reach	O
a	O
definitive	O
diagnosis	O
,	O
the	O
patient	O
underwent	O
repeat	B-Detailed_description
EUS	B-Diagnostic_procedure
and	O
biopsy	B-Diagnostic_procedure
was	O
performed	O
.	O

On	O
endoscopy	B-Diagnostic_procedure
,	O
a	O
2	B-Area
×	I-Area
1	I-Area
-	I-Area
cm	I-Area
columnar	B-Sign_symptom
uplift	I-Sign_symptom
in	O
the	O
terminal	B-Biological_structure
ileum	I-Biological_structure
and	O
multiple	B-Detailed_description
submucosal	B-Biological_structure
lesions	B-Sign_symptom
in	O
the	O
rectum	B-Biological_structure
were	O
identified	O
(	O
Fig	O
.	O
3	O
)	O
.	O

EUS	B-Diagnostic_procedure
revealed	O
that	O
the	O
lesions	B-Sign_symptom
in	O
the	O
terminal	B-Biological_structure
ileum	I-Biological_structure
were	O
sized	O
1	B-Area
.	I-Area
6	I-Area
×	I-Area
1	I-Area
.	I-Area
2	I-Area
cm	I-Area
and	O
the	O
lesions	B-Sign_symptom
in	O
the	O
rectum	B-Biological_structure
were	O
sized	O
almost	O
0	B-Area
.	I-Area
6	I-Area
×	I-Area
1	I-Area
.	I-Area
0	I-Area
cm	I-Area
,	O
they	O
were	O
all	O
homogeneously	B-Detailed_description
hypoechoic	I-Detailed_description
and	O
originated	B-Detailed_description
from	I-Detailed_description
the	I-Detailed_description
muscularis	I-Detailed_description
mucosa	I-Detailed_description
layer	I-Detailed_description
.	O

Pathological	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
of	O
the	O
biopsied	O
specimens	O
from	O
the	O
lesions	B-Sign_symptom
of	O
the	O
rectum	B-Biological_structure
showed	O
diffuse	O
lymphomatous	B-Detailed_description
proliferation	I-Detailed_description
and	O
dense	B-Detailed_description
infiltration	I-Detailed_description
by	O
monomorphic	B-Biological_structure
,	I-Biological_structure
small	I-Biological_structure
cleaved	I-Biological_structure
cells	I-Biological_structure
with	I-Biological_structure
irregularly	I-Biological_structure
shaped	I-Biological_structure
nuclei	I-Biological_structure
(	O
Fig	O
.	O
4	O
)	O
.	O

On	O
immunohistochemical	B-Diagnostic_procedure
analysis	I-Diagnostic_procedure
,	O
the	O
cells	O
were	O
positive	B-Lab_value
for	O
cyclin	B-Diagnostic_procedure
D1	I-Diagnostic_procedure
,	O
CD20	B-Diagnostic_procedure
,	O
CD21	B-Diagnostic_procedure
,	O
SOX	B-Diagnostic_procedure
-	I-Diagnostic_procedure
11	I-Diagnostic_procedure
,	O
and	O
Bcl	B-Diagnostic_procedure
-	I-Diagnostic_procedure
2	I-Diagnostic_procedure
,	O
but	O
negative	B-Lab_value
for	O
CD3	B-Diagnostic_procedure
and	O
CD10	B-Diagnostic_procedure
,	O
which	O
was	O
compatible	O
with	O
the	O
diagnosis	O
of	O
MCL	B-Disease_disorder
.	O

Ki	B-Diagnostic_procedure
-	I-Diagnostic_procedure
67	I-Diagnostic_procedure
staining	I-Diagnostic_procedure
revealed	O
a	O
proliferative	B-Lab_value
index	I-Lab_value
of	I-Lab_value
30	I-Lab_value
%	I-Lab_value
.	O

Based	O
on	O
these	O
findings	O
,	O
the	O
diagnosis	O
of	O
Ann	B-Lab_value
Arbor	I-Lab_value
stage	I-Lab_value
IV	I-Lab_value
MCL	B-Disease_disorder
was	O
confirmed	O
.	O

The	O
patient	O
was	O
referred	O
for	O
combination	O
chemotherapy	B-Medication
with	O
rituximab	B-Medication
,	O
cyclophosphamide	B-Medication
,	O
doxorubicin	B-Medication
,	O
vincristine	B-Medication
,	O
and	O
prednisone	B-Medication
(	O
R	B-Medication
-	I-Medication
CHOP	I-Medication
regimen	I-Medication
)	O
.	O

The	O
patient	O
has	O
been	O
in	O
remission	B-Sign_symptom
clinically	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
75	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
man	O
was	O
referred	O
to	O
our	O
hospital	B-Nonbiological_location
for	O
the	O
evaluation	O
of	O
dysphagia	B-Sign_symptom
for	O
9	B-Duration
months	I-Duration
.	O

He	O
had	O
associated	O
symptoms	O
of	O
nausea	B-Sign_symptom
and	O
vomiting	B-Sign_symptom
but	O
denied	O
hematemesis	B-Sign_symptom
,	O
hematochezia	B-Sign_symptom
,	O
lethargy	B-Sign_symptom
,	O
and	O
dyspnea	B-Sign_symptom
.	O

He	O
was	O
an	O
active	O
smoker	O
and	O
consumed	O
alcohol	O
for	O
30	O
years	O
.	O

Physical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
revealed	O
no	O
peripheral	B-Detailed_description
lymphadenopathy	B-Sign_symptom
,	O
thyromegaly	B-Sign_symptom
,	O
ascites	B-Sign_symptom
,	O
or	O
mass	B-Sign_symptom
in	O
the	O
abdomen	B-Biological_structure
.	O

Laboratory	B-Diagnostic_procedure
data	I-Diagnostic_procedure
were	O
normal	B-Lab_value
:	O
HBs	B-Diagnostic_procedure
-	I-Diagnostic_procedure
Ag	I-Diagnostic_procedure
negative	B-Lab_value
,	O
HIV	B-Diagnostic_procedure
negative	B-Lab_value
,	O
and	O
syphilis	B-Diagnostic_procedure
negative	B-Lab_value
.	O

Test	O
for	O
serum	B-Diagnostic_procedure
antibody	I-Diagnostic_procedure
against	I-Diagnostic_procedure
Helicobacter	I-Diagnostic_procedure
pylori	I-Diagnostic_procedure
was	O
negative	B-Lab_value
.	O

Chest	B-Biological_structure
computed	B-Diagnostic_procedure
tomography	I-Diagnostic_procedure
(	O
CT	B-Diagnostic_procedure
)	O
was	O
notable	O
for	O
a	O
huge	B-Detailed_description
well	B-Detailed_description
-	I-Detailed_description
circumscribed	I-Detailed_description
and	O
homogeneous	B-Detailed_description
cylindrical	B-Shape
mesenchymal	B-Detailed_description
neoplasm	B-Sign_symptom
measuring	O
15	B-Volume
.	I-Volume
5	I-Volume
×	I-Volume
5	I-Volume
.	I-Volume
9	I-Volume
×	I-Volume
4	I-Volume
.	I-Volume
0	I-Volume
cm	I-Volume
in	O
lower	B-Biological_structure
and	I-Biological_structure
middle	I-Biological_structure
esophagus	I-Biological_structure
with	O
mild	B-Detailed_description
contrast	I-Detailed_description
enhancement	I-Detailed_description
(	O
Fig	O
.	O
1A	O
)	O
.	O

CT	B-Diagnostic_procedure
revealed	O
no	O
abnormalities	B-Sign_symptom
in	O
the	O
lungs	B-Biological_structure
,	O
heart	B-Biological_structure
,	O
ribs	B-Biological_structure
,	O
or	O
mediastinum	B-Biological_structure
.	O

Endoscopic	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
showed	O
a	O
submucosal	B-Detailed_description
lesion	B-Sign_symptom
in	O
the	O
esophagus	B-Biological_structure
starting	O
at	O
20	B-Distance
cm	I-Distance
from	I-Distance
the	I-Distance
incisor	I-Distance
teeth	I-Distance
extending	O
up	B-Biological_structure
to	I-Biological_structure
the	I-Biological_structure
cardia	I-Biological_structure
(	O
Fig	O
.	O
1B	O
)	O
.	O

Endoscopic	B-Diagnostic_procedure
ultrasonography	I-Diagnostic_procedure
(	O
EUS	B-Diagnostic_procedure
)	O
revealed	O
hypoechoic	B-Detailed_description
lesion	B-Sign_symptom
with	O
a	O
clear	B-Detailed_description
boundary	I-Detailed_description
located	O
in	O
the	O
4th	B-Detailed_description
layer	I-Detailed_description
.	O

The	O
mass	O
appeared	O
as	O
a	O
benign	B-Sign_symptom
tumor	I-Sign_symptom
and	O
was	O
preoperatively	O
diagnosed	O
as	O
esophageal	B-Disease_disorder
leiomyoma	I-Disease_disorder
based	O
on	O
chest	O
CT	O
,	O
endoscopic	O
examination	O
,	O
and	O
EUS	O
findings	O
.	O

Endoscopic	B-Detailed_description
mucosal	B-Detailed_description
resection	B-Therapeutic_procedure
or	O
endoscopic	B-Detailed_description
submucosal	B-Detailed_description
resection	B-Therapeutic_procedure
was	O
not	O
possible	O
because	O
of	O
large	O
size	O
.	O

Hence	O
,	O
surgical	B-Detailed_description
resection	B-Therapeutic_procedure
was	O
planned	O
and	O
informed	O
written	O
consent	O
was	O
taken	O
.	O

The	O
patient	O
underwent	O
thoracoscopic	B-Detailed_description
-	I-Detailed_description
assisted	I-Detailed_description
resection	B-Therapeutic_procedure
of	O
the	O
mass	O
with	O
gastroesophageal	B-Detailed_description
anastomosis	B-Therapeutic_procedure
,	O
thoracic	B-Biological_structure
duct	I-Biological_structure
ligation	B-Therapeutic_procedure
,	O
and	O
jejunostomy	B-Therapeutic_procedure
.	O

Postoperative	B-Therapeutic_procedure
course	I-Therapeutic_procedure
was	O
uneventful	B-Lab_value
.	O

Grossly	O
,	O
a	O
spindle	B-Shape
shaped	I-Shape
lump	B-Sign_symptom
measuring	O
14	B-Volume
×	I-Volume
3	I-Volume
.	I-Volume
5	I-Volume
×	I-Volume
2	I-Volume
.	I-Volume
5	I-Volume
cm	I-Volume
,	O
was	O
observed	O
in	O
the	O
resected	O
esophagus	B-Biological_structure
,	O
which	O
grew	O
into	O
the	O
esophageal	B-Biological_structure
lumen	I-Biological_structure
and	O
blocked	B-Sign_symptom
most	O
of	O
lumen	B-Biological_structure
.	O

This	O
lump	O
located	O
in	O
the	O
submucosa	B-Biological_structure
was	O
covered	B-Detailed_description
with	I-Detailed_description
intact	I-Detailed_description
mucosa	I-Detailed_description
,	O
without	O
erosion	B-Sign_symptom
,	O
ulcer	B-Disease_disorder
,	O
and	O
hemorrhage	B-Disease_disorder
.	O

Its	O
cut	O
surface	O
was	O
homogenously	B-Color
white	I-Color
to	O
grayish	B-Color
-	I-Color
white	I-Color
in	O
color	O
.	O

Histological	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
using	O
hematoxylin	B-Diagnostic_procedure
and	O
eosin	B-Diagnostic_procedure
staining	I-Diagnostic_procedure
revealed	O
that	O
tumor	O
was	O
covered	B-Detailed_description
with	I-Detailed_description
intact	I-Detailed_description
squamous	I-Detailed_description
epithelium	I-Detailed_description
,	O
arising	O
from	B-Biological_structure
the	I-Biological_structure
submucosal	I-Biological_structure
layer	I-Biological_structure
and	O
expanding	O
in	O
to	O
the	O
muscular	B-Biological_structure
layer	I-Biological_structure
.	O

The	O
tumor	O
was	O
composed	B-Detailed_description
of	I-Detailed_description
many	I-Detailed_description
nodules	I-Detailed_description
of	I-Detailed_description
varying	I-Detailed_description
sizes	I-Detailed_description
separated	I-Detailed_description
by	I-Detailed_description
collagen	I-Detailed_description
fibers	I-Detailed_description
.	O

Numerous	B-Detailed_description
cytoplasm	I-Detailed_description
-	I-Detailed_description
rich	I-Detailed_description
cells	I-Detailed_description
were	I-Detailed_description
observed	I-Detailed_description
in	I-Detailed_description
the	I-Detailed_description
collagenous	I-Detailed_description
septations	I-Detailed_description
with	I-Detailed_description
invasive	I-Detailed_description
growth	I-Detailed_description
pattern	I-Detailed_description
(	O
Fig	O
.	O
2A	O
-	O
C	O
)	O
.	O

The	O
nodules	B-Detailed_description
were	I-Detailed_description
mainly	I-Detailed_description
composed	I-Detailed_description
of	I-Detailed_description
small	I-Detailed_description
to	I-Detailed_description
mid	I-Detailed_description
-	I-Detailed_description
sized	I-Detailed_description
centrocyte	I-Detailed_description
-	I-Detailed_description
like	I-Detailed_description
or	I-Detailed_description
monocyte	I-Detailed_description
-	I-Detailed_description
like	I-Detailed_description
cells	I-Detailed_description
arranged	I-Detailed_description
in	I-Detailed_description
diffuse	I-Detailed_description
pattern	I-Detailed_description
.	O

These	O
atypical	B-Detailed_description
lymphocytes	I-Detailed_description
possessed	O
clear	B-Detailed_description
boundary	I-Detailed_description
,	O
pale	B-Detailed_description
cytoplasm	I-Detailed_description
,	O
irregular	B-Detailed_description
nucleus	I-Detailed_description
,	O
and	O
occasional	B-Detailed_description
nucleolus	I-Detailed_description
(	O
Fig	O
.	O
2D	O
)	O
.	O

Mitosis	B-Diagnostic_procedure
was	O
rare	B-Lab_value
.	O

No	O
lymphoepithelial	B-Detailed_description
lesion	B-Sign_symptom
was	O
recognized	O
in	O
the	O
lesion	O
.	O

On	O
immunohistochemical	B-Diagnostic_procedure
staining	I-Diagnostic_procedure
,	O
epithelium	B-Biological_structure
was	O
diffusely	B-Lab_value
positive	I-Lab_value
for	O
cytokeratin	B-Diagnostic_procedure
(	O
Fig	O
.	O
3A	O
)	O
,	O
and	O
the	O
tumor	O
cells	O
were	O
diffusely	B-Lab_value
positive	I-Lab_value
for	O
cluster	B-Diagnostic_procedure
of	I-Diagnostic_procedure
differentiation	I-Diagnostic_procedure
(	I-Diagnostic_procedure
CD	I-Diagnostic_procedure
)	I-Diagnostic_procedure
20	I-Diagnostic_procedure
,	O
paired	B-Diagnostic_procedure
box	I-Diagnostic_procedure
5	I-Diagnostic_procedure
(	O
Fig	O
.	O
3B	O
)	O
,	O
and	O
B	B-Diagnostic_procedure
-	I-Diagnostic_procedure
cell	I-Diagnostic_procedure
lymphoma	I-Diagnostic_procedure
(	I-Diagnostic_procedure
Bcl	I-Diagnostic_procedure
)	I-Diagnostic_procedure
-	I-Diagnostic_procedure
2	I-Diagnostic_procedure
(	O
Fig	O
.	O
3D	O
)	O
.	O

Small	B-Biological_structure
deposits	I-Biological_structure
of	I-Biological_structure
tumor	I-Biological_structure
cells	I-Biological_structure
,	O
which	O
were	O
distributed	O
mainly	B-Detailed_description
in	I-Detailed_description
the	I-Detailed_description
collagen	I-Detailed_description
fibers	I-Detailed_description
,	O
were	O
positive	B-Lab_value
for	O
multiple	B-Diagnostic_procedure
myeloma	I-Diagnostic_procedure
oncogene	I-Diagnostic_procedure
1	I-Diagnostic_procedure
,	O
CD138	B-Diagnostic_procedure
,	O
and	O
CD43	B-Diagnostic_procedure
.	O

Several	B-Biological_structure
tumor	I-Biological_structure
cells	I-Biological_structure
were	O
also	O
positive	B-Lab_value
for	O
CD30	B-Diagnostic_procedure
.	O

Small	B-Biological_structure
lymphocytes	I-Biological_structure
were	O
positive	B-Lab_value
for	O
CD3	B-Diagnostic_procedure
and	O
CD5	B-Diagnostic_procedure
.	O

Follicular	B-Biological_structure
dendritic	I-Biological_structure
cells	I-Biological_structure
were	O
positive	B-Lab_value
for	O
CD21	B-Diagnostic_procedure
and	O
CD23	B-Diagnostic_procedure
(	O
Fig	O
.	O
3C	O
)	O
.	O

All	B-Biological_structure
cells	I-Biological_structure
were	O
negative	B-Lab_value
for	O
CyclinD1	B-Diagnostic_procedure
,	O
CD10	B-Diagnostic_procedure
,	O
Bcl	B-Diagnostic_procedure
-	I-Diagnostic_procedure
6	I-Diagnostic_procedure
,	O
and	O
B	B-Diagnostic_procedure
lymphocyte	I-Diagnostic_procedure
specific	I-Diagnostic_procedure
activation	I-Diagnostic_procedure
of	I-Diagnostic_procedure
OCT	I-Diagnostic_procedure
binding	I-Diagnostic_procedure
protein	I-Diagnostic_procedure
1	I-Diagnostic_procedure
.	O

These	O
follicular	O
dendritic	O
cells	O
were	O
arranged	O
in	O
nodules	O
in	O
which	O
the	O
tumor	O
cells	O
were	O
relatively	O
evenly	O
distributed	O
.	O

This	O
pattern	O
was	O
suggestive	O
of	O
follicular	O
colonizations	O
seen	O
in	O
MALT	B-Disease_disorder
lymphoma	I-Disease_disorder
.	O

In	O
this	O
case	O
,	O
gene	B-Diagnostic_procedure
rearragements	I-Diagnostic_procedure
and	I-Diagnostic_procedure
clonality	I-Diagnostic_procedure
analysis	I-Diagnostic_procedure
of	O
immunoglobulin	B-Diagnostic_procedure
heavy	I-Diagnostic_procedure
chain	I-Diagnostic_procedure
gene	I-Diagnostic_procedure
,	O
kappa	B-Diagnostic_procedure
light	I-Diagnostic_procedure
chain	I-Diagnostic_procedure
gene	I-Diagnostic_procedure
,	O
and	O
lambda	B-Diagnostic_procedure
light	I-Diagnostic_procedure
chain	I-Diagnostic_procedure
gene	I-Diagnostic_procedure
was	O
performed	O
using	O
the	O
IdentiCloneTM	B-Detailed_description
IGH	I-Detailed_description
/	I-Detailed_description
IGK	I-Detailed_description
/	I-Detailed_description
IGL	I-Detailed_description
Gene	I-Detailed_description
Clonality	I-Detailed_description
Assay	I-Detailed_description
(	O
InVivoScribe	B-Detailed_description
Technologies	I-Detailed_description
,	I-Detailed_description
CA	I-Detailed_description
)	O
.	O

On	O
monoclonal	O
gene	O
rearrangement	O
,	O
1	B-Lab_value
band	I-Lab_value
appeared	I-Lab_value
within	I-Lab_value
150	I-Lab_value
to	I-Lab_value
175	I-Lab_value
base	I-Lab_value
pairs	I-Lab_value
(	O
bp	O
)	O
in	O
heavy	O
chain	O
gene	O
,	O
2	B-Lab_value
discrete	I-Lab_value
bands	I-Lab_value
within	I-Lab_value
225	I-Lab_value
to	I-Lab_value
250	I-Lab_value
bp	I-Lab_value
in	O
kappa	O
light	O
chain	O
gene	O
,	O
and	O
1	B-Lab_value
band	I-Lab_value
within	I-Lab_value
125	I-Lab_value
to	I-Lab_value
150	I-Lab_value
bp	I-Lab_value
in	O
lambda	O
light	O
chain	O
gene	O
(	O
Fig	O
.	O
4	O
)	O
.	O

In	O
addition	O
,	O
no	O
Epstein	B-Disease_disorder
-	I-Disease_disorder
Barr	I-Disease_disorder
virus	I-Disease_disorder
was	O
observed	O
in	O
this	O
lymphoma	O
on	O
in	B-Diagnostic_procedure
situ	I-Diagnostic_procedure
hybridization	I-Diagnostic_procedure
using	O
the	O
EB	B-Detailed_description
virus	I-Detailed_description
-	I-Detailed_description
encoded	I-Detailed_description
small	I-Detailed_description
RNA	I-Detailed_description
(	O
Fig	O
.	O
3E	O
,	O
F	O
)	O
.	O

Based	O
on	O
the	O
clinical	O
data	O
,	O
pathological	O
,	O
immunohistochemical	O
,	O
and	O
gene	O
rearragements	O
analysis	O
,	O
final	O
diagnosis	O
of	O
primary	B-Detailed_description
esophageal	B-Biological_structure
MALT	B-Disease_disorder
lymphoma	I-Disease_disorder
was	O
made	O
.	O

After	O
the	O
surgical	B-Detailed_description
resection	B-Therapeutic_procedure
,	O
no	O
additional	O
therapy	B-Therapeutic_procedure
in	O
the	O
form	O
of	O
chemotherapy	B-Medication
or	O
radiotherapy	B-Therapeutic_procedure
was	O
administered	O
.	O

Over	O
the	O
8	B-Duration
months	I-Duration
of	O
follow	O
-	O
up	O
,	O
no	O
evidence	O
of	O
recurrence	B-Sign_symptom
or	O
metastases	B-Sign_symptom
was	O
found	O
on	O
CT	B-Diagnostic_procedure
and	O
the	O
patient	O
has	O
been	O
asymptomatic	B-Sign_symptom
.	O

Ethical	O
approval	O
for	O
this	O
study	O
was	O
obtained	O
from	O
Medical	O
Ethics	O
Committee	O
of	O
the	O
Third	O
Affiliated	O
Hospital	O
,	O
the	O
Third	O
Military	O
Medical	O
University	O
.	O

Written	O
informed	O
consent	O
was	O
obtained	O
from	O
the	O
patient	O
for	O
the	O
publication	O
of	O
this	O
case	O
report	O
and	O
the	O
accompanying	O
images	O
.	O

-DOCSTART- -X- -X- -X- O

n	O
March	O
2015	O
,	O
a	O
62	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
woman	O
was	O
admitted	O
to	O
our	O
hospital	B-Nonbiological_location
.	O

She	O
complained	O
of	O
progressive	B-Detailed_description
visual	B-Sign_symptom
disturbance	I-Sign_symptom
,	O
which	O
began	O
about	O
4	O
years	O
ago	O
and	O
was	O
treated	O
as	O
cataract	B-Disease_disorder
in	O
local	B-Nonbiological_location
hospital	I-Nonbiological_location
,	O
but	O
no	O
relief	B-Sign_symptom
was	O
seen	O
.	O

On	O
the	O
contrary	O
,	O
the	O
symptoms	B-Sign_symptom
aggravated	O
half	O
a	O
year	O
ago	O
,	O
together	O
with	O
headache	B-Sign_symptom
,	O
left	B-Biological_structure
eye	I-Biological_structure
pain	B-Sign_symptom
,	O
tearing	B-Sign_symptom
and	O
increased	O
secretions	B-Sign_symptom
,	O
and	O
the	O
computed	B-Diagnostic_procedure
tomography	I-Diagnostic_procedure
(	O
CT	B-Diagnostic_procedure
)	O
scan	O
of	O
the	O
brain	B-Biological_structure
in	O
local	B-Nonbiological_location
hospital	I-Nonbiological_location
showed	O
a	O
sellar	B-Biological_structure
region	I-Biological_structure
lesion	B-Sign_symptom
.	O

Besides	O
,	O
2	O
years	O
earlier	O
,	O
the	O
patient	O
underwent	O
resection	B-Therapeutic_procedure
of	O
melanoma	B-Disease_disorder
in	O
the	O
left	B-Biological_structure
heel	I-Biological_structure
(	O
T2N0M0	B-Lab_value
,	O
ki67	B-Lab_value
3	I-Lab_value
-	I-Lab_value
5	I-Lab_value
%	I-Lab_value
,	O
Stage	B-Lab_value
II	I-Lab_value
)	O
,	O
followed	O
by	O
resection	B-Therapeutic_procedure
of	O
the	O
recurred	B-Detailed_description
melanoma	B-Disease_disorder
nearby	B-Biological_structure
the	I-Biological_structure
primary	I-Biological_structure
site	I-Biological_structure
15	O
months	O
later	O
(	O
T3N3M0	B-Lab_value
,	O
Stage	B-Lab_value
III	I-Lab_value
)	O
,	O
without	O
lymphadenectomy	B-Therapeutic_procedure
.	O

She	O
had	O
no	O
family	O
history	O
of	O
melanoma	O
.	O

On	O
physical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
,	O
the	O
patient	O
had	O
bilateral	B-Detailed_description
temporal	B-Detailed_description
hemianopsia	B-Sign_symptom
,	O
the	O
right	B-Diagnostic_procedure
finger	I-Diagnostic_procedure
counting	I-Diagnostic_procedure
was	O
1	B-Lab_value
m	I-Lab_value
,	O
and	O
the	O
left	B-Diagnostic_procedure
finger	I-Diagnostic_procedure
counting	I-Diagnostic_procedure
was	O
no	B-Lab_value
more	I-Lab_value
than	I-Lab_value
0	I-Lab_value
.	I-Lab_value
5	I-Lab_value
m	I-Lab_value
.	O

Enlarged	B-Sign_symptom
lymph	B-Biological_structure
nodes	I-Biological_structure
were	O
palpable	O
in	O
the	O
right	B-Biological_structure
groin	I-Biological_structure
.	O

On	O
ophthalmologic	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
,	O
the	O
patient	O
had	O
right	B-Diagnostic_procedure
vision	I-Diagnostic_procedure
of	O
0	B-Lab_value
.	I-Lab_value
4	I-Lab_value
and	O
left	B-Diagnostic_procedure
vision	I-Diagnostic_procedure
of	O
0	B-Lab_value
.	I-Lab_value
08	I-Lab_value
,	O
with	O
the	O
same	O
intraocular	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
15	B-Lab_value
mm	I-Lab_value
Hg	I-Lab_value
bilaterally	B-Detailed_description
.	O

The	O
optometry	B-Diagnostic_procedure
found	O
the	O
right	B-Biological_structure
eye	I-Biological_structure
of	O
+6	B-Lab_value
.	I-Lab_value
00DS	I-Lab_value
/	I-Lab_value
+0	I-Lab_value
.	I-Lab_value
25DC	I-Lab_value
∗	I-Lab_value
65	I-Lab_value
°	I-Lab_value
and	O
the	O
left	B-Biological_structure
eye	I-Biological_structure
of	O
+6	B-Lab_value
.	I-Lab_value
25DS	I-Lab_value
/	I-Lab_value
+0	I-Lab_value
.	I-Lab_value
50DC	I-Lab_value
∗	I-Lab_value
20	I-Lab_value
°	I-Lab_value
.	O

The	O
patient	O
had	O
maculopathy	B-Disease_disorder
of	O
both	B-Biological_structure
eyes	I-Biological_structure
and	O
optic	B-Disease_disorder
atrophy	I-Disease_disorder
of	O
the	O
left	B-Biological_structure
eye	I-Biological_structure
.	O

Light	B-Diagnostic_procedure
reflex	I-Diagnostic_procedure
and	O
eye	B-Diagnostic_procedure
movement	I-Diagnostic_procedure
of	O
both	B-Biological_structure
eyes	I-Biological_structure
were	O
normal	B-Lab_value
.	O

CT	B-Diagnostic_procedure
scans	O
of	O
the	O
brain	B-Biological_structure
parenchyma	I-Biological_structure
,	O
orbital	B-Biological_structure
,	O
and	O
chest	B-Biological_structure
were	O
unremarkable	B-Lab_value
.	O

CT	B-Diagnostic_procedure
scan	O
and	O
ultrasound	B-Diagnostic_procedure
examination	O
of	O
the	O
abdomen	B-Biological_structure
showed	O
hepatic	B-Biological_structure
portal	I-Biological_structure
and	O
retroperitoneal	B-Biological_structure
lymphadenectasis	B-Sign_symptom
and	O
enlarged	B-Sign_symptom
left	B-Biological_structure
lobe	I-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
liver	I-Biological_structure
with	O
substantial	B-Severity
placeholder	B-Detailed_description
lesions	B-Sign_symptom
.	O

Ultrasound	B-Diagnostic_procedure
examination	O
of	O
bilateral	B-Detailed_description
inguinal	B-Biological_structure
lymph	I-Biological_structure
nodes	I-Biological_structure
discovered	O
multiple	B-Detailed_description
low	B-Sign_symptom
echo	I-Sign_symptom
light	I-Sign_symptom
groups	I-Sign_symptom
,	O
the	O
largest	B-Distance
of	I-Distance
which	I-Distance
was	I-Distance
31	I-Distance
mm	I-Distance
in	O
diameter	O
,	O
with	O
hilus	B-Detailed_description
of	I-Detailed_description
the	I-Detailed_description
echo	I-Detailed_description
and	O
asymmetrical	B-Detailed_description
thickening	B-Sign_symptom
of	O
the	O
skin	B-Biological_structure
.	O

CT	B-Diagnostic_procedure
scan	O
of	O
sellar	B-Biological_structure
region	I-Biological_structure
revealed	O
a	O
crumby	B-Texture
mass	B-Sign_symptom
,	O
protruding	O
out	O
of	O
the	O
sphenoid	B-Biological_structure
sinus	I-Biological_structure
,	O
with	O
obscure	B-Detailed_description
boundary	I-Detailed_description
and	O
bone	B-Detailed_description
destruction	I-Detailed_description
.	O

And	O
the	O
average	B-Detailed_description
CT	B-Diagnostic_procedure
value	I-Diagnostic_procedure
of	O
the	O
mass	B-Sign_symptom
was	O
46	B-Lab_value
HU	I-Lab_value
.	O

Sellar	B-Biological_structure
region	I-Biological_structure
magnetic	B-Diagnostic_procedure
resonance	I-Diagnostic_procedure
imaging	I-Diagnostic_procedure
(	O
MRI	B-Diagnostic_procedure
)	O
revealed	O
a	O
round	B-Shape
mass	B-Sign_symptom
of	O
30	B-Distance
mm	I-Distance
in	O
diameter	O
in	O
the	O
enlarged	B-Biological_structure
sellae	I-Biological_structure
(	O
Fig	O
.	O
1A	O
,	O
B	O
)	O
.	O

The	O
mass	O
showed	O
isointense	B-Sign_symptom
in	O
T1	B-Diagnostic_procedure
-	I-Diagnostic_procedure
weighted	I-Diagnostic_procedure
images	I-Diagnostic_procedure
(	O
T1	B-Diagnostic_procedure
-	I-Diagnostic_procedure
WI	I-Diagnostic_procedure
)	O
and	O
T2	B-Diagnostic_procedure
-	I-Diagnostic_procedure
weighted	I-Diagnostic_procedure
images	I-Diagnostic_procedure
(	O
T2	B-Diagnostic_procedure
-	I-Diagnostic_procedure
WI	I-Diagnostic_procedure
)	O
,	O
with	O
homogeneous	B-Detailed_description
enhancement	B-Sign_symptom
after	O
Gadolinium	B-Detailed_description
-	I-Detailed_description
DTPA	I-Detailed_description
injection	I-Detailed_description
,	O
and	O
dural	B-Detailed_description
tail	I-Detailed_description
sign	I-Detailed_description
was	O
seen	O
.	O

Small	O
foci	O
inside	O
the	O
tumor	O
showed	O
hyperintense	B-Sign_symptom
signals	I-Sign_symptom
in	O
T1	B-Diagnostic_procedure
-	I-Diagnostic_procedure
WI	I-Diagnostic_procedure
and	O
hypointense	B-Sign_symptom
signals	I-Sign_symptom
in	O
T2	B-Diagnostic_procedure
-	I-Diagnostic_procedure
WI	I-Diagnostic_procedure
,	O
without	B-Detailed_description
enhancement	I-Detailed_description
.	O

And	O
it	O
was	O
seen	O
that	O
the	O
mass	O
penetrated	O
meninges	B-Biological_structure
,	O
surrounded	O
the	O
left	B-Biological_structure
internal	I-Biological_structure
carotid	I-Biological_structure
artery	I-Biological_structure
,	O
and	O
was	O
blurred	O
with	O
the	O
left	B-Biological_structure
optic	I-Biological_structure
nerve	I-Biological_structure
.	O

Pituitary	B-Biological_structure
stalk	I-Biological_structure
became	O
shorter	B-Sign_symptom
with	O
a	O
right	B-Detailed_description
displacement	I-Detailed_description
.	O

Laboratory	B-Diagnostic_procedure
findings	I-Diagnostic_procedure
revealed	O
increased	B-Lab_value
levels	O
of	O
prolactin	B-Diagnostic_procedure
(	O
119	B-Lab_value
.	I-Lab_value
08	I-Lab_value
μg	I-Lab_value
/	I-Lab_value
L	I-Lab_value
,	O
normal	O
range	O
5	O
.	O
99	O
-	O
30	O
.	O
04	O
μg	O
/	O
L	O
)	O
and	O
cortisol	B-Diagnostic_procedure
(	O
677	B-Lab_value
.	I-Lab_value
10	I-Lab_value
nmol	I-Lab_value
/	I-Lab_value
L	I-Lab_value
,	O
normal	O
range	O
118	O
.	O
60	O
-	O
618	O
.	O
00	O
nmol	O
/	O
L	O
)	O
and	O
decreased	B-Lab_value
levels	O
of	O
free	B-Diagnostic_procedure
thyroxine	I-Diagnostic_procedure
(	O
FT4	B-Diagnostic_procedure
)	O
(	O
6	B-Lab_value
.	I-Lab_value
04	I-Lab_value
pmol	I-Lab_value
/	I-Lab_value
L	I-Lab_value
,	O
normal	O
range	O
12	O
.	O
00	O
-	O
22	O
.	O
00	O
pmol	O
/	O
L	O
)	O
and	O
free	B-Diagnostic_procedure
triiodothyronine	I-Diagnostic_procedure
(	O
FT3	B-Diagnostic_procedure
)	O
(	O
2	B-Lab_value
.	I-Lab_value
09	I-Lab_value
pmol	I-Lab_value
/	I-Lab_value
L	I-Lab_value
,	O
normal	O
range	O
3	O
.	O
50	O
-	O
6	O
.	O
50	O
pmol	O
/	O
L	O
)	O
.	O

The	O
patient	O
was	O
diagnosed	O
with	O
a	O
giant	B-Detailed_description
prolactinoma	B-Disease_disorder
.	O

The	O
patient	O
underwent	O
transnasal	B-Detailed_description
transsphenoidal	B-Detailed_description
surgery	B-Therapeutic_procedure
to	O
remove	O
the	O
tumor	O
and	O
relieve	O
the	O
compression	O
of	O
the	O
optic	O
nerve	O
.	O

Intraoperatively	O
,	O
it	O
was	O
seen	O
that	O
the	O
tumor	B-Sign_symptom
invaded	O
and	O
filled	O
the	O
left	B-Biological_structure
interval	I-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
sphenoid	I-Biological_structure
sinus	I-Biological_structure
,	O
and	O
part	O
of	O
bone	B-Biological_structure
in	I-Biological_structure
sellar	I-Biological_structure
floor	I-Biological_structure
and	O
left	B-Biological_structure
side	I-Biological_structure
parasellar	I-Biological_structure
was	O
destroyed	B-Sign_symptom
and	O
absorbed	B-Sign_symptom
.	O

A	O
little	B-Detailed_description
normal	I-Detailed_description
pituitary	I-Detailed_description
tissue	I-Detailed_description
was	I-Detailed_description
seen	I-Detailed_description
in	I-Detailed_description
the	I-Detailed_description
top	I-Detailed_description
right	I-Detailed_description
of	O
tumor	O
in	O
the	O
sellar	B-Biological_structure
turcica	I-Biological_structure
.	O

The	O
tumor	O
was	O
reddish	B-Color
black	I-Color
with	O
extremely	B-Detailed_description
rich	I-Detailed_description
blood	I-Detailed_description
supply	I-Detailed_description
and	O
had	O
close	B-Detailed_description
adhesion	I-Detailed_description
to	I-Detailed_description
the	I-Detailed_description
surrounding	I-Detailed_description
structure	I-Detailed_description
.	O

The	O
texture	O
in	O
the	O
center	O
of	O
the	O
tumor	O
was	O
soft	B-Texture
and	O
much	B-Texture
tougher	I-Texture
over	I-Texture
the	I-Texture
rim	I-Texture
.	O

Intraoperative	B-Detailed_description
frozen	B-Diagnostic_procedure
-	I-Diagnostic_procedure
section	I-Diagnostic_procedure
examination	I-Diagnostic_procedure
found	O
melanin	B-Sign_symptom
granules	I-Sign_symptom
,	O
and	O
it	O
was	O
considered	O
to	O
be	O
malignant	B-Disease_disorder
melanoma	I-Disease_disorder
or	O
meningioma	B-Disease_disorder
.	O

The	O
tumor	O
cells	O
were	O
composed	O
of	O
eosinophilic	B-Detailed_description
staining	I-Detailed_description
epithelial	I-Detailed_description
cells	I-Detailed_description
.	O

Most	O
of	O
cell	B-Diagnostic_procedure
nuclei	I-Diagnostic_procedure
were	O
round	B-Shape
,	O
a	O
few	O
were	O
reniform	B-Lab_value
and	O
hippocrepiform	B-Lab_value
with	O
evident	B-Lab_value
nucleoli	B-Diagnostic_procedure
,	O
and	O
nuclear	B-Diagnostic_procedure
fission	I-Diagnostic_procedure
was	O
seen	B-Lab_value
.	O

The	O
tumor	O
showed	O
no	O
evidence	O
of	O
necrosis	B-Sign_symptom
(	O
Fig	O
.	O
2	O
)	O
.	O

The	O
tumor	O
was	O
immunopositive	B-Lab_value
focally	B-Detailed_description
for	O
melanoma	B-Diagnostic_procedure
-	I-Diagnostic_procedure
specific	I-Diagnostic_procedure
markers	I-Diagnostic_procedure
such	O
as	O
S	B-Diagnostic_procedure
-	I-Diagnostic_procedure
100	I-Diagnostic_procedure
,	O
HMB45	B-Diagnostic_procedure
,	O
and	O
Vimentin	B-Diagnostic_procedure
,	O
and	O
immunopositive	B-Lab_value
for	O
neuroendocrine	B-Diagnostic_procedure
tumor	I-Diagnostic_procedure
markers	I-Diagnostic_procedure
such	O
as	O
CgA	B-Diagnostic_procedure
and	O
Syn	B-Diagnostic_procedure
(	O
Fig	O
.	O
3	O
)	O
.	O

The	O
Ki67	B-Diagnostic_procedure
index	I-Diagnostic_procedure
was	O
3	B-Lab_value
%	I-Lab_value
to	I-Lab_value
5	I-Lab_value
%	I-Lab_value
;	O
it	O
was	O
higher	B-Lab_value
in	O
metastatic	B-Detailed_description
melanoma	I-Detailed_description
than	I-Detailed_description
in	I-Detailed_description
the	I-Detailed_description
adenomatous	I-Detailed_description
component	I-Detailed_description
.	O

Taken	O
the	O
melanoma	O
history	O
and	O
suspected	O
lymph	O
node	O
and	O
hepatic	O
metastasis	O
into	O
consideration	O
,	O
the	O
patient	O
was	O
diagnosised	O
with	O
MMPA	B-Disease_disorder
.	O

After	O
surgery	O
,	O
significant	O
relief	B-Lab_value
was	O
seen	O
in	O
visual	B-Diagnostic_procedure
field	I-Diagnostic_procedure
and	O
headache	B-Sign_symptom
,	O
and	O
the	O
level	O
of	O
prolactin	B-Diagnostic_procedure
,	O
cortisol	B-Diagnostic_procedure
,	O
and	O
FT4	B-Diagnostic_procedure
returned	O
to	O
normal	B-Lab_value
with	O
hormone	B-Medication
replacement	I-Medication
therapy	I-Medication
.	O

Because	O
the	O
focal	O
liver	O
lesions	O
and	O
lymphadenectasis	O
did	O
not	O
cause	O
much	O
discomfort	B-Sign_symptom
,	O
the	O
patient	O
refused	O
any	O
further	O
surgical	B-Therapeutic_procedure
intervention	I-Therapeutic_procedure
or	O
other	O
treatment	O
.	O

She	O
was	O
discharged	O
from	O
the	O
hospital	B-Nonbiological_location
immediately	O
and	O
was	O
disease	B-Disease_disorder
free	O
until	O
2	O
months	O
after	O
the	O
third	O
surgery	O
.	O

The	O
patient	O
successively	O
found	O
new	O
melanoma	B-Disease_disorder
metastatic	B-Sign_symptom
sites	I-Sign_symptom
in	O
the	O
skin	B-Biological_structure
of	I-Biological_structure
lower	I-Biological_structure
left	I-Biological_structure
leg	I-Biological_structure
,	O
knees	O
,	O
the	O
upper	B-Biological_structure
left	I-Biological_structure
leg	I-Biological_structure
,	O
the	O
left	B-Biological_structure
groin	I-Biological_structure
and	O
the	O
right	B-Biological_structure
groin	I-Biological_structure
,	O
and	O
the	O
right	B-Biological_structure
leg	I-Biological_structure
.	O

At	O
the	O
follow	O
-	O
up	O
in	O
late	O
January	O
2016	O
,	O
the	O
patient	O
could	O
not	O
walk	B-Activity
and	O
live	B-Activity
by	I-Activity
herself	I-Activity
and	O
was	O
depressed	B-Disease_disorder
.	O

At	O
the	O
latest	O
follow	O
-	O
up	O
,	O
in	O
late	O
January	O
,	O
2017	O
,	O
the	O
patient	O
was	O
alive	B-Sign_symptom
with	O
worse	O
symptoms	B-Sign_symptom
,	O
she	O
had	O
sensory	B-Sign_symptom
deficits	I-Sign_symptom
of	O
both	B-Biological_structure
legs	I-Biological_structure
,	O
which	O
could	B-Sign_symptom
not	I-Sign_symptom
move	I-Sign_symptom
,	O
hyperalgesia	B-Sign_symptom
of	O
hands	B-Biological_structure
and	O
mouth	B-Biological_structure
,	O
impaired	B-Sign_symptom
intelligence	I-Sign_symptom
,	O
but	O
she	O
lived	O
well	O
with	O
the	O
disease	O
by	O
careful	O
nursing	O
of	O
her	O
daughter	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
23	B-Age
year	I-Age
old	I-Age
white	O
male	O
with	O
a	O
4	B-Duration
year	I-Duration
history	O
of	O
Crohn	B-Disease_disorder
`	I-Disease_disorder
s	I-Disease_disorder
disease	I-Disease_disorder
presented	O
with	O
an	O
acute	O
two	B-Duration
day	I-Duration
history	O
of	O
malaise	B-Sign_symptom
,	O
fever	B-Sign_symptom
,	O
abdominal	B-Biological_structure
pain	B-Sign_symptom
,	O
vomiting	B-Sign_symptom
and	O
stomal	B-Biological_structure
diarrhoea	B-Sign_symptom
.	O

He	O
complained	O
of	O
joint	B-Biological_structure
pains	B-Sign_symptom
affecting	O
the	O
shoulders	B-Biological_structure
,	O
elbows	B-Biological_structure
,	O
wrists	B-Biological_structure
,	O
metacarpophalangeals	B-Biological_structure
,	O
knees	B-Biological_structure
and	O
ankles	B-Biological_structure
.	O

There	O
was	O
also	O
a	O
rash	B-Sign_symptom
on	O
the	O
elbows	B-Biological_structure
,	O
ankles	B-Biological_structure
and	O
feet	B-Biological_structure
,	O
which	O
began	O
as	O
erythematous	B-Detailed_description
macules	B-Sign_symptom
and	O
evolved	O
to	O
vesico	B-Detailed_description
-	I-Detailed_description
pustular	I-Detailed_description
lesions	B-Sign_symptom
followed	O
by	O
crusting	B-Sign_symptom
.	O

There	O
was	O
no	O
history	O
of	O
sexual	O
exposure	O
or	O
any	O
intercurrent	O
infection	B-Sign_symptom
.	O

He	O
was	O
on	O
no	B-Medication
regular	I-Medication
medication	I-Medication
,	O
but	O
had	O
discontinued	O
Pentasa	B-Medication
4	O
months	O
earlier	O
.	O

One	O
month	O
earlier	O
he	O
had	O
undergone	O
a	O
laparotomy	B-Therapeutic_procedure
to	O
excise	O
a	O
complex	B-Detailed_description
ileo	B-Detailed_description
-	I-Detailed_description
cutaneous	I-Detailed_description
fistula	B-Sign_symptom
with	O
blind	B-Detailed_description
tracts	I-Detailed_description
,	O
and	O
two	O
weeks	O
earlier	O
a	O
defunctioning	B-Detailed_description
ileostomy	B-Therapeutic_procedure
had	O
been	O
created	O
in	O
view	O
of	O
persistent	B-Detailed_description
abdominal	B-Biological_structure
pain	B-Sign_symptom
.	O

The	O
cutaneous	B-Biological_structure
fistula	B-Sign_symptom
had	B-Duration
been	I-Duration
present	I-Duration
for	I-Duration
a	I-Duration
year	I-Duration
,	O
but	O
was	O
associated	O
with	O
a	O
terminal	B-Detailed_description
ileal	B-Biological_structure
stricture	B-Sign_symptom
and	O
ileo	B-Biological_structure
-	I-Biological_structure
rectal	I-Biological_structure
fistula	B-Sign_symptom
of	B-Duration
at	I-Duration
least	I-Duration
2	I-Duration
years	I-Duration
duration	I-Duration
.	O

His	O
bowel	O
disease	O
had	O
been	O
resistant	O
to	O
immunosuppressive	O
drugs	O
including	O
azathioprine	B-Medication
,	O
corticosteroiods	B-Medication
and	O
three	B-Dosage
infusions	I-Dosage
of	O
Infliximab	B-Medication
a	O
year	O
earlier	O
.	O

There	O
had	O
been	O
no	B-Sign_symptom
extra	I-Sign_symptom
-	I-Sign_symptom
intestinal	I-Sign_symptom
manifestations	I-Sign_symptom
.	O

On	O
admission	O
to	O
the	O
hospital	B-Nonbiological_location
,	O
he	O
was	O
thin	B-Sign_symptom
,	O
afebrile	B-Sign_symptom
with	O
a	O
resting	B-Detailed_description
tachycardia	B-Sign_symptom
of	O
125	B-Lab_value
/	I-Lab_value
minute	I-Lab_value
.	O

The	O
rest	O
of	O
the	O
cardio	B-Diagnostic_procedure
-	I-Diagnostic_procedure
respiratory	I-Diagnostic_procedure
examination	I-Diagnostic_procedure
was	O
normal	B-Lab_value
.	O

The	O
abdomen	B-Biological_structure
was	O
minimally	B-Severity
tender	B-Sign_symptom
around	O
the	O
ileostomy	B-Biological_structure
without	B-Detailed_description
guarding	I-Detailed_description
or	I-Detailed_description
rebound	I-Detailed_description
tenderness	I-Detailed_description
.	O

Examination	B-Diagnostic_procedure
of	I-Diagnostic_procedure
the	I-Diagnostic_procedure
skin	I-Diagnostic_procedure
revealed	O
some	O
pustules	B-Sign_symptom
and	O
crusts	B-Sign_symptom
around	O
the	O
elbows	B-Biological_structure
,	O
ankles	B-Biological_structure
and	O
feet	B-Biological_structure
(	O
Fig	O
1	O
and	O
2	O
)	O
.	O

The	B-Other_event
buttocks	I-Other_event
were	I-Other_event
spared	I-Other_event
.	I-Other_event

There	O
were	O
clinical	O
signs	O
of	O
synovitis	B-Sign_symptom
of	O
the	O
wrists	B-Biological_structure
,	O
proximal	B-Biological_structure
interphalangeal	I-Biological_structure
and	O
metacarpophalangeal	B-Biological_structure
joints	B-Biological_structure
,	O
and	O
also	O
both	B-Biological_structure
ankles	I-Biological_structure
.	O

Results	O
of	O
the	O
laboratory	B-Diagnostic_procedure
tests	I-Diagnostic_procedure
showed	O
a	O
haemoglobin	B-Diagnostic_procedure
of	O
13	B-Lab_value
.	I-Lab_value
1	I-Lab_value
gm	I-Lab_value
/	I-Lab_value
dl	I-Lab_value
,	O
white	B-Diagnostic_procedure
blood	I-Diagnostic_procedure
count	I-Diagnostic_procedure
15	B-Lab_value
.	I-Lab_value
8	I-Lab_value
×	I-Lab_value
109	I-Lab_value
/	I-Lab_value
L	I-Lab_value
,	O
platelets	B-Diagnostic_procedure
585	B-Lab_value
×	I-Lab_value
109	I-Lab_value
/	I-Lab_value
L	I-Lab_value
,	O
C	B-Diagnostic_procedure
-	I-Diagnostic_procedure
reactive	I-Diagnostic_procedure
protein	I-Diagnostic_procedure
37	B-Lab_value
.	I-Lab_value
7	I-Lab_value
mg	I-Lab_value
/	I-Lab_value
L	I-Lab_value
and	O
erythrocyte	B-Diagnostic_procedure
sedimentation	I-Diagnostic_procedure
rate	I-Diagnostic_procedure
69	B-Lab_value
mm	I-Lab_value
/	I-Lab_value
hr	I-Lab_value
.	O

Urea	B-Diagnostic_procedure
and	O
electrolytes	B-Diagnostic_procedure
,	O
complement	B-Diagnostic_procedure
,	O
urine	B-Diagnostic_procedure
analysis	I-Diagnostic_procedure
and	O
microscopy	B-Diagnostic_procedure
were	O
normal	B-Lab_value
.	O

Rheumatoid	B-Diagnostic_procedure
factor	I-Diagnostic_procedure
,	O
antinuclear	B-Detailed_description
and	O
antineutrophil	B-Detailed_description
cytoplasmic	B-Diagnostic_procedure
antibodies	I-Diagnostic_procedure
,	O
cryoglobulins	B-Diagnostic_procedure
and	O
Hepatitis	B-Diagnostic_procedure
B	I-Diagnostic_procedure
and	I-Diagnostic_procedure
C	I-Diagnostic_procedure
serology	I-Diagnostic_procedure
were	O
negative	B-Lab_value
.	O

Transthoracic	B-Biological_structure
echocardiogram	B-Diagnostic_procedure
showed	O
no	B-Sign_symptom
signs	I-Sign_symptom
of	I-Sign_symptom
endocarditis	I-Sign_symptom
,	O
and	O
multiple	B-Diagnostic_procedure
blood	I-Diagnostic_procedure
cultures	I-Diagnostic_procedure
were	O
sterile	B-Lab_value
.	O

A	O
skin	B-Biological_structure
biopsy	B-Diagnostic_procedure
from	O
the	O
ankle	O
revealed	O
a	O
perivascular	B-Biological_structure
lymphohistiocytic	B-Biological_structure
infiltrate	B-Biological_structure
with	O
prominent	O
neutrophils	B-Biological_structure
and	O
associated	O
fibrinoid	B-Detailed_description
necrosis	B-Sign_symptom
of	O
vessels	B-Biological_structure
consistent	O
with	O
`	O
leukocytoclastic	B-Detailed_description
`	O
vasculitis	B-Disease_disorder
.	O

He	O
was	O
commenced	O
on	O
60	B-Dosage
mg	I-Dosage
prednisolone	B-Medication
per	B-Dosage
day	I-Dosage
leading	O
to	O
prompt	B-Detailed_description
and	O
complete	B-Detailed_description
resolution	B-Sign_symptom
of	I-Sign_symptom
all	I-Sign_symptom
features	I-Sign_symptom
.	O

The	O
dose	O
of	O
prednisolone	B-Medication
was	O
rapidly	O
tapered	O
over	B-Duration
the	I-Duration
course	I-Duration
of	I-Duration
one	I-Duration
month	I-Duration
by	O
the	O
patient	O
,	O
faster	O
than	O
advised	O
but	O
without	B-Sign_symptom
any	I-Sign_symptom
recurrence	I-Sign_symptom
over	B-Duration
the	I-Duration
following	I-Duration
3	I-Duration
years	I-Duration
.	O

-DOCSTART- -X- -X- -X- O

A	O
69	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
woman	O
with	O
a	O
history	O
of	O
hypertension	B-Disease_disorder
presented	O
with	O
a	O
generalized	B-Detailed_description
petechial	B-Detailed_description
rash	B-Sign_symptom
and	O
shortness	B-Sign_symptom
of	I-Sign_symptom
breath	I-Sign_symptom
of	O
3	B-Duration
days	I-Duration
duration	I-Duration
.	O

The	O
rash	O
was	O
nonpruritic	B-Detailed_description
,	O
painless	B-Detailed_description
,	O
and	O
started	O
at	O
the	O
thighs	B-Biological_structure
,	O
but	O
rapidly	O
disseminated	O
to	O
the	O
rest	B-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
body	I-Biological_structure
.	O

She	O
had	O
progressive	B-Detailed_description
dyspnea	B-Sign_symptom
on	O
exertion	B-Detailed_description
,	O
with	O
a	O
significant	O
decrease	B-Lab_value
in	O
exercise	B-Diagnostic_procedure
tolerance	I-Diagnostic_procedure
.	O

She	O
denied	O
fever	B-Sign_symptom
,	O
headache	B-Sign_symptom
,	O
dizziness	B-Sign_symptom
,	O
hemoptysis	B-Sign_symptom
,	O
or	O
bleeding	B-Sign_symptom
from	O
anywhere	B-Biological_structure
.	O

There	O
was	O
no	O
history	O
of	O
new	O
drug	O
use	O
,	O
unusual	B-Activity
food	I-Activity
intake	I-Activity
,	O
contact	O
with	O
any	O
sick	O
persons	O
,	O
or	O
recent	O
travel	B-Activity
.	O

Her	O
only	O
medication	O
was	O
enalapril	B-Medication
,	O
which	O
she	O
had	O
been	O
taking	O
for	O
several	B-Duration
years	I-Duration
.	O

The	O
patient	O
denied	O
any	O
use	O
of	O
recreational	B-Activity
drugs	I-Activity
,	O
tobacco	B-Activity
,	O
or	O
alcohol	B-Activity
.	O

On	O
admission	O
,	O
she	O
was	O
afebrile	B-Sign_symptom
,	O
normotensive	B-Sign_symptom
with	O
mild	B-Severity
tachypnea	B-Sign_symptom
(	O
respiratory	B-Diagnostic_procedure
rate	I-Diagnostic_procedure
of	O
22	B-Lab_value
breaths	I-Lab_value
per	I-Lab_value
minute	I-Lab_value
)	O
.	O

Physical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
revealed	O
scattered	O
petechial	B-Detailed_description
rash	B-Sign_symptom
,	O
more	O
prominent	O
in	O
lower	B-Biological_structure
extremities	I-Biological_structure
,	O
nonpalpable	B-Detailed_description
and	O
nonblanching	B-Detailed_description
.	O

Chest	B-Diagnostic_procedure
auscultation	I-Diagnostic_procedure
revealed	O
coarse	B-Detailed_description
crackles	B-Sign_symptom
bilaterally	B-Detailed_description
.	O

Cardiovascular	B-Biological_structure
,	O
abdominal	B-Biological_structure
,	O
and	O
neurological	B-Detailed_description
examinations	B-Diagnostic_procedure
were	O
normal	B-Lab_value
.	O

There	O
was	O
no	O
palpable	O
lymphadenopathy	B-Sign_symptom
or	O
visceromegaly	B-Sign_symptom
.	O

Laboratory	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
revealed	O
thrombocytopenia	B-Sign_symptom
(	O
platelets	B-Diagnostic_procedure
7000	B-Lab_value
/	I-Lab_value
μL	I-Lab_value
)	O
,	O
anemia	B-Sign_symptom
(	O
hemoglobin	B-Diagnostic_procedure
10	B-Lab_value
.	I-Lab_value
8	I-Lab_value
mg	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
and	O
hematocrit	B-Diagnostic_procedure
34	B-Lab_value
%	I-Lab_value
)	O
,	O
and	O
leukocytosis	B-Sign_symptom
(	O
white	B-Diagnostic_procedure
blood	I-Diagnostic_procedure
cells	I-Diagnostic_procedure
[	O
WBCs	B-Diagnostic_procedure
]	O
11,600	B-Lab_value
/	I-Lab_value
μL	I-Lab_value
)	O
.	O

The	O
coagulation	B-Diagnostic_procedure
profile	I-Diagnostic_procedure
was	O
normal	B-Lab_value
,	O
which	O
excluded	O
disseminated	B-Disease_disorder
intravascular	I-Disease_disorder
coagulation	I-Disease_disorder
.	O

Arterial	B-Diagnostic_procedure
blood	I-Diagnostic_procedure
gas	I-Diagnostic_procedure
on	O
ambient	B-Detailed_description
air	I-Detailed_description
revealed	O
a	O
partial	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
of	I-Diagnostic_procedure
oxygen	I-Diagnostic_procedure
(	O
PaO2	B-Diagnostic_procedure
)	O
of	O
64	B-Lab_value
Torr	I-Lab_value
,	O
a	O
partial	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
of	I-Diagnostic_procedure
carbon	I-Diagnostic_procedure
dioxide	I-Diagnostic_procedure
(	O
PaCO2	B-Diagnostic_procedure
)	O
of	O
37	B-Lab_value
Torr	I-Lab_value
(	O
pH	B-Diagnostic_procedure
7	B-Lab_value
.	I-Lab_value
45	I-Lab_value
)	O
,	O
and	O
an	O
increased	B-Lab_value
alveolar	B-Diagnostic_procedure
-	I-Diagnostic_procedure
arterial	I-Diagnostic_procedure
gradient	I-Diagnostic_procedure
(	O
44	B-Lab_value
Torr	I-Lab_value
)	O
.	O

Diffuse	B-Detailed_description
airspace	B-Sign_symptom
consolidation	I-Sign_symptom
was	O
found	O
on	O
chest	B-Biological_structure
roentgenogram	B-Diagnostic_procedure
(	O
Fig	O
.	O
1A	O
)	O
.	O

Computed	B-Diagnostic_procedure
tomography	I-Diagnostic_procedure
(	O
CT	B-Diagnostic_procedure
)	O
of	O
the	O
chest	B-Biological_structure
showed	O
diffuse	B-Detailed_description
ground	B-Texture
glass	I-Texture
alveolar	B-Biological_structure
opacities	B-Sign_symptom
and	O
patchy	B-Detailed_description
infiltrates	B-Sign_symptom
(	O
Fig	O
.	O
1B	O
,	O
C	O
)	O
.	O

She	O
was	O
started	O
on	O
broad	B-Detailed_description
-	I-Detailed_description
spectrum	I-Detailed_description
antibiotics	B-Medication
and	O
received	O
intravenous	O
steroids	B-Medication
.	O

Peripheral	B-Diagnostic_procedure
smear	I-Diagnostic_procedure
showed	O
giant	B-Sign_symptom
platelets	I-Sign_symptom
and	O
occasional	B-Detailed_description
small	B-Detailed_description
platelet	B-Sign_symptom
clumps	I-Sign_symptom
,	O
with	O
no	O
schistocytes	B-Sign_symptom
.	O

A	O
flexible	B-Diagnostic_procedure
fiber	I-Diagnostic_procedure
-	I-Diagnostic_procedure
optic	I-Diagnostic_procedure
bronchoscopy	I-Diagnostic_procedure
(	O
FFB	B-Diagnostic_procedure
)	O
showed	O
normal	B-Lab_value
mucosa	B-Diagnostic_procedure
with	O
no	O
endobronchial	B-Biological_structure
lesions	B-Sign_symptom
(	O
Fig	O
.	O
2A	O
)	O
.	O

Serial	O
aliquots	O
of	O
BAL	B-Diagnostic_procedure
fluid	I-Diagnostic_procedure
(	O
BALF	B-Diagnostic_procedure
)	O
turned	O
more	O
hemorrhagic	B-Sign_symptom
,	O
confirming	O
the	O
bronchoscopic	O
diagnosis	O
of	O
DAH	B-Disease_disorder
(	O
Fig	O
.	O
2B	O
)	O
.	O

Cytology	B-Diagnostic_procedure
of	O
BALF	O
showed	O
a	O
substantial	O
amount	O
of	O
hemosiderin	B-Detailed_description
-	I-Detailed_description
laden	I-Detailed_description
macrophages	B-Sign_symptom
,	O
further	O
supporting	O
the	O
diagnosis	O
.	O

All	O
BALF	O
cultures	B-Diagnostic_procedure
and	O
gram	B-Diagnostic_procedure
stains	I-Diagnostic_procedure
were	O
negative	B-Lab_value
.	O

The	O
patient	O
remained	O
with	O
severe	B-Severity
thrombocytopenia	B-Sign_symptom
and	O
hypoxia	B-Sign_symptom
despite	O
steroids	B-Medication
and	O
platelets	B-Medication
transfusion	I-Medication
.	O

High	B-Dosage
doses	I-Dosage
of	O
pulse	O
steroids	B-Medication
and	O
intravenous	O
immunoglobulins	B-Medication
(	O
IVIGs	O
)	O
were	O
added	O
with	O
clinico	B-Detailed_description
-	I-Detailed_description
radiological	I-Detailed_description
improvement	B-Sign_symptom
.	O

A	O
bone	B-Diagnostic_procedure
marrow	I-Diagnostic_procedure
aspirate	I-Diagnostic_procedure
was	O
morphologically	B-Lab_value
normal	I-Lab_value
.	O

Additional	O
laboratory	B-Diagnostic_procedure
studies	I-Diagnostic_procedure
failed	B-Lab_value
to	I-Lab_value
reveal	I-Lab_value
an	I-Lab_value
etiology	I-Lab_value
for	O
secondary	O
thrombocytopenia	B-Sign_symptom
(	O
Table	O
1	O
)	O
,	O
supporting	O
the	O
diagnosis	O
of	O
ITP	B-Disease_disorder
.	O

Steroids	B-Medication
were	O
gradually	O
tapered	O
.	O

Repeat	O
chest	B-Biological_structure
radiograph	B-Diagnostic_procedure
showed	O
almost	O
complete	O
resolution	O
of	O
bilateral	B-Detailed_description
infiltrates	B-Sign_symptom
(	O
Fig	O
.	O
3	O
)	O
.	O

Platelet	B-Diagnostic_procedure
count	I-Diagnostic_procedure
returned	O
to	O
normal	B-Lab_value
by	O
week	O
10	O
after	O
admission	O
without	O
any	O
additional	B-Therapeutic_procedure
therapies	I-Therapeutic_procedure
(	O
Fig	O
.	O
4	O
)	O
.	O

